Search Result

Results for "

11��-Hydroxysteroid Dehydrogenase Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (19) 17β-HSD (4) Aldehyde Dehydrogenase (ALDH) (23) Dihydroorotate Dehydrogenase (47) Isocitrate Dehydrogenase (IDH) (19) Lactate Dehydrogenase (24) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (6) PDHK (14) Phosphoglycerate Dehydrogenase (PHGDH) (6) 5-HT Receptor (2) AIM2 (1) Amyloid-β (2) Androgen Receptor (2) Angiotensin Receptor (1) Antibiotic (9) Apoptosis (21) Arenavirus (1) ATP Synthase (1) Autophagy (8) Bacterial (17) Bcl-2 Family (3) Biochemical Assay Reagents (7) Cannabinoid Receptor (1) Caspase (2) Cytochrome P450 (3) DNA/RNA Synthesis (29) Drug Metabolite (4) Endogenous Metabolite (91) Ferroptosis (1) Flavivirus (5) Fluorescent Dye (3) Formyl Peptide Receptor (FPR) (1) Fungal (24) FXR (2) Glucocorticoid Receptor (1) HBV (3) HCV (3) Histamine Receptor (2) HIV (2) HSP (1) Influenza Virus (5) Interleukin Related (3) Isotope-Labeled Compounds (9) JNK (1) MDM-2/p53 (3) Mineralocorticoid Receptor (1) Mitochondrial Metabolism (3) NKCC (1) NOD-like Receptor (NLR) (1) Nucleoside Antimetabolite/Analog (4) Orthopoxvirus (1) Parasite (14) PARP (7) PDI (1) PKC (1) Prostaglandin Receptor (2) Pyroptosis (1) Reactive Oxygen Species (7) SARS-CoV (3) Sirtuin (3) Small Interfering RNA (siRNA) (1) Thrombin (1) Transketolase (1) VEGFR (1) Virus Protease (1)
By Research Areas:	Cancer (138) Cardiovascular Disease (14) Endocrinology (10) Infection (73) Inflammation/Immunology (47) Metabolic Disease (108) Neurological Disease (13)
Click Chemistry:	Alkynes (4)

364

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

123

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: 11β-HSD Lactate Dehydrogenase Dihydroorotate Dehydrogenase Isocitrate Dehydrogenase (IDH) Methylenetetrahydrofolate Dehydrogenase (MTHFD) Phosphoglycerate Dehydrogenase (PHGDH) Aldehyde Dehydrogenase (ALDH) 17β-HSD SHP2 PDHK 15-PGDH

Cat. No.	Product Name	Target	Research Areas

HY-E70014

Glucose 1-dehydrogenase FAD-GDH	Endogenous Metabolite	Others
Glucose 1-dehydrogenase, or glucose dehydrogenase (FAD)/Pseudomonas glucose dehydrogenase. Glucose 1-dehydrogenase is an enzyme used as a regeneration cofactor to convert glucose and NAD(P) into NAD(P)H and gluconic acid.

HY-E70003

Glutamate dehydrogenase	Biochemical Assay Reagents	Endocrinology
Glutamate dehydrogenase is an enzyme in both prokaryotes and eukaryotic mitochondria. Glutamate dehydrogenase can be used for the enzymatic determination of ammonia, alpha-ketoglutaric acid, L-glutamate and urease.

HY-113165A

Isobutyryl-L-carnitine chloride

Endogenous Metabolite Metabolic Disease

Isobutyryl-L-carnitine chloride is a product of the acyl-CoA dehydrogenases.

Isobutyryl-L-carnitine chloride	Endogenous Metabolite	Metabolic Disease
Isobutyryl-L-carnitine chloride is a product of the acyl-CoA dehydrogenases.

HY-P2725

Glycerol dehydrogenase	Endogenous Metabolite	Metabolic Disease
Glycerol dehydrogenase is a polyol dehydrogenase that catalyzes the NAD-dependent oxidation of glycerol to dihydroxyacetone. Glycerol dehydrogenase can be used for glycerol metabolism in diverse microorganisms.

HY-125552

Chlorothricin

Antibiotic Infection Inflammation/Immunology

Chlorothricin, an antibiotic, is an Inhibitor of porcine-heart malate dehydrogenases.

Chlorothricin	Antibiotic	Infection Inflammation/Immunology
Chlorothricin, an antibiotic, is an Inhibitor of porcine-heart malate dehydrogenases.

HY-P2807

L-Lactate dehydrogenase	Endogenous Metabolite	Inflammation/Immunology
L-Lactate dehydrogenase is a redox enzyme. L-Lactate dehydrogenase catalyzes the reduction of pyruvate to L-lactate by NADH in vivo with absolute enantiospecificity.

HY-P3186

*Glucose dehydrogenase* (GDH)**	Endogenous Metabolite	Metabolic Disease
Glucose dehydrogenase (GDH) is a oxidoreductase. Glucose dehydrogenase (GDH) catalyzes the oxidation of β-D-glucose to β-D-glucono-1,5-lactone with simultaneous reduction of the cofactor NADP⁺ to NADPH or, to a lesser extent, NAD⁺ to NADH. Glucose dehydrogenase (GDH) accepts both NAD⁺ and NADP⁺ as cofactors and can be used for the regeneration of NADH and NADPH.

HY-118980

*Sorbitol dehydrogenase-IN-1*	Others	Metabolic Disease
Sorbitol dehydrogenase-IN-1 is a potent and orally active sorbitol dehydrogenase inhibitor with IC₅₀ s of 4, 5 nM for rat and human, respectively.

HY-P2907

Formate dehydrogenase	Endogenous Metabolite	Others
Formate dehydrogenase is an enzyme ubiquitous in prokaryotes and eukaryotes that catalyzes the reversible oxidation of formate to carbon dioxide. According to its metal content, structure and catalytic strategy, Formate dehydrogenase can be divided into two categories, non-metallic and metal-containing, which are often used in biochemical research.

HY-P2854

Alanine dehydrogenase

Endogenous Metabolite Metabolic Disease

Alanine dehydrogenase is a microbial enzyme that catalyzes a reversible conversion of L-alanine to pyruvate.

Alanine dehydrogenase	Endogenous Metabolite	Metabolic Disease
Alanine dehydrogenase is a microbial enzyme that catalyzes a reversible conversion of L-alanine to pyruvate.

HY-125863

Glucose-6-phosphate dehydrogenase	Endogenous Metabolite	Cancer Metabolic Disease
Glucose-6-phosphate dehydrogenase is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase is a major source of NADPH that is required by many essential cellular systems including the antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 system, and others. Glucose-6-phosphate dehydrogenase can be used for the research of diabetes, aldosterone-induced endothelial dysfunction, and cancer.

HY-P3185

beta-Galactose dehydrogenase	Endogenous Metabolite	Metabolic Disease
beta-Galactose dehydrogenase can make conversion of galactose to galactonolactone and the concomitant reduction of NAD to the fluorescent NADH. beta-Galactose dehydrogenase can be used for the determination of galactose.

HY-P2993

Isocitrate dehydrogenase ICDH	Isocitrate Dehydrogenase (IDH)	Metabolic Disease
Isocitrate dehydrogenase (ICDH) is a citric acid or tricarboxylic acid cycle enzyme, is often used in biochemical studies. Isocitrate dehydrogenase catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate and reduces NAD(P)⁺ to NAD(P)H, it plays important roles in cellular metabolism.

HY-P2994

3-Hydroxybutyrate dehydrogenase 3-HBDH	Endogenous Metabolite	Others
3-Hydroxybutyrate dehydrogenase (3-HBDH) is a mitochondrial enzyme, is often used in biochemical studies. 3-hydroxybutyrate dehydrogenase is involved in the synthesis and degradation of ketone bodies and butanoate metabolism. 3-Hydroxybutyrate dehydrogenase catalyzes (R)-3-hydroxybutanoate converts into acetoacetate.

HY-P2911

*Glutamate dehydrogenase* (NAD(P))** GLDH	Mitochondrial Metabolism	Others
Glutamate dehydrogenase NAD(P) (GLDH) can be found in hepatocytes, renal tissue, brain, muscle, and intestinal cells. Glutamate dehydrogenase NAD(P) is often used in biochemical studies. Glutamate dehydrogenase is a mitochondrial enzyme, it catalyzes the reversible oxidative deamination of glutamate to α-ketoglutarate (α-KG) as part of the urea cycle.

HY-P2765

Glycerol phosphate dehydrogenase GPDH	Endogenous Metabolite	Metabolic Disease
Glycerol phosphate dehydrogenase catalyzes the conversion of dihydroxyacetone phosphate to α-glycerol phosphate.

HY-125954B

Uridine diphosphate galuronic acid trisodium UDP-α-D-galuronic acid trisodium	Biochemical Assay Reagents	Metabolic Disease
Uridine diphosphate galuronic acid (UDP-α-D-galuronic acid) trisodium is a cofactor that is formed by the catalytic activity of UDP-glucose dehydrogenase.

HY-P2897

D-Lactate dehydrogenase D-LDH	Lactate Dehydrogenase	Others
D-Lactate dehydrogenase (D-LDH) is an oxidoreductase that uses NAD⁺ or NADP⁺ as an acceptor and acts on the donor CH-OH group, and can catalyze the oxidation of D-lactate to pyruvate. D-Lactate dehydrogenase widely exists in bacteria and fungi, and is often used in biochemical research.

HY-P2740

Alcohol dehydrogenase EC 1.1.1.1	Endogenous Metabolite	Metabolic Disease
Alcohol dehydrogenase is a dimeric protein in the cytosol of cells. Alcohol dehydrogenase, the key enzyme for alcohol consumption in the body, is the highest expressed in the liver and participates in the detoxification mechanism of environmental alcohol.

HY-W004784

3-Butynoic acid	Endogenous Metabolite	Others
3-Butynoic acid is an inhibitor of acyl CoA dehydrogenase. 3-Butynoic acid is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-E70075

*α-Glycerophosphate Dehydrogenase-Triosephosphate* GDH-TIM; GDH-TPI	Transketolase	Metabolic Disease
α-Glycerophosphate Dehydrogenase-Triosephosphate (GDH-TIM) is an enzyme mixture composed of glycerol phosphate dehydrogenase (GDH) and triphosphate isomerase (TIM). α-Glycerophosphate Dehydrogenase-Triosephosphate can be used to determine the activity of transketolase (TK) in hemolytic substances of red blood cells to evaluate vitamin B deficiency.

HY-33914

4-Hydroxymethylpyrazole	Endogenous Metabolite	Others
4-Hydroxymethylpyrazole is the primary metabolite of Fomepizole (HY-B0876). Fomepizole is a competitive inhibitor of the enzyme alcohol dehydrogenase.

HY-P2768

Leucine dehydrogenase LDH, EC 1.4.1.9	Endogenous Metabolite	Metabolic Disease
Leucine dehydrogenase can be purified from Bacillus spheroides. Leucine dehydrogenase catalyzed the oxidative deamination of L-leucine, L-valine, L-isoleucine, L-norvaline, L-alpha-aminobutyrate, and L-norleucine, and the reductive amination of their keto analogues.

HY-119976

Boscalid

Fungal Infection

Boscalid is an anti-fungal agent. Boscalid is a succinate dehydrogenase (SDH) inhibitor.

Boscalid	Fungal	Infection
Boscalid is an anti-fungal agent. Boscalid is a *succinate dehydrogenase* (SDH)** inhibitor.

HY-P2809

Malate dehydrogenase EC 1.1.1.37; MDH	Endogenous Metabolite	Metabolic Disease
Malate dehydrogenase (MDH) catalyzes the mutual conversion of oxaloacetate and malate, and is associated with the oxidation/reduction of dinucleotide coenzymes.

HY-P2901

3α-Hydroxysteroid dehydrogenase 3α-HSD	Endogenous Metabolite	Endocrinology
3α-Hydroxysteroid dehydrogenase (3α-HSD) is an enzyme encoded by the AKR1C4 gene, which can catalyze the conversion of 3-ketosteroids into 3α-hydroxy compounds. 3α-Hydroxysteroid dehydrogenase plays an important role in the inactivation of androgen DHT, and can convert DHT into 3α-androstanediol with weak androgen activity, which can be used in the research of hirsutism.

HY-Z0031

(R)-(-)-1,2-Propanediol	Endogenous Metabolite	Metabolic Disease
(R)-(-)-1,2-Propanediol is a (R)-enantiomer of 1,2-Propanediol that produced from glucose in Escherichia coli expressing NADH-linked glycerol dehydrogenase genes.

HY-B1877

Nitrofen

Others Cancer

Nitrofen is a selective contact herbicide. Nitrofen is a retinal dehydrogenase and protoporphyrinogen oxidase inhibitor.
HY-150127

Pydiflumetofen

Fungal Infection

Pydiflumetofen is a new generation of succinate dehydrogenase inhibitor fungicide.

Nitrofen	Others	Cancer
Nitrofen is a selective contact herbicide. Nitrofen is a retinal dehydrogenase and protoporphyrinogen oxidase inhibitor.

Pydiflumetofen	Fungal	Infection
Pydiflumetofen is a new generation of succinate dehydrogenase inhibitor fungicide.

HY-P2947

ALDH Aldehyde Dehydrogenase (NAD(P))	Aldehyde Dehydrogenase (ALDH)	Others
ALDH (Aldehyde dehydrogenase (NAD(P))) catalyzes the oxidation of aldehydes into their corresponding carboxylic acids with the concomitant reduction of the cofactor NAD(P) into NAD(P)H, is often used in biochemical studies. The ALDHs are one of many enzyme systems the body utilizes to alleviate aldehyde stress.

HY-W012926

Dihydrouracil 5,6-Dihydrouracil	Endogenous Metabolite	Metabolic Disease
Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient.

HY-103391

Qc1

Others Metabolic Disease

Qc1 is a reversible and noncompetitive threonine dehydrogenase (TDH) inhibitor. Qc1 can be used for the research of Metabolic disease.
HY-41648

IDH1 Inhibitor 8

Isocitrate Dehydrogenase (IDH) Cancer

IDH1 Inhibitor 8 (91) is isocitrate dehydrogenase 1 (IDH1) inhibitor. IDH1 Inhibitor 8 can be used for the research of cancer.

Qc1	Others	Metabolic Disease
Qc1 is a reversible and noncompetitive threonine dehydrogenase (TDH) inhibitor. Qc1 can be used for the research of Metabolic disease.

IDH1 Inhibitor 8	Isocitrate Dehydrogenase (IDH)	Cancer
IDH1 Inhibitor 8 (91) is isocitrate dehydrogenase 1 (IDH1) inhibitor. IDH1 Inhibitor 8 can be used for the research of cancer.

HY-135658

hDHODH-IN-1	DNA/RNA Synthesis Dihydroorotate Dehydrogenase	Inflammation/Immunology
hDHODH-IN-1 is a *human dihydroorotate dehydrogenase* (hDHODH)** inhibitor. hDHODH-IN-1 has anti-inflammatory effect.

HY-149601

SDH-IN-8

Fungal Infection

SDH-IN-8 (compound G40) is a potent succinate dehydrogenase (SDH) inhibitor with an IC₅₀ of 27 nM for porcine SDH. SDH-IN-8 has fungicidal properties.
HY-149600

SDH-IN-7

Fungal Infection

SDH-IN-7 (compound G28) is a potent succinate dehydrogenase (SDH) inhibitor with an IC₅₀ of 26 nM for porcine SDH. SDH-IN-7 has fungicidal properties.

SDH-IN-8	Fungal	Infection
SDH-IN-8 (compound G40) is a potent *succinate dehydrogenase* (SDH) inhibitor with an IC₅₀** of 27 nM for porcine SDH. SDH-IN-8 has fungicidal properties.

SDH-IN-7	Fungal	Infection
SDH-IN-7 (compound G28) is a potent *succinate dehydrogenase* (SDH) inhibitor with an IC₅₀** of 26 nM for porcine SDH. SDH-IN-7 has fungicidal properties.

HY-132606

Nedosiran DCR-PHXC	Small Interfering RNA (siRNA)	Metabolic Disease
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate.

HY-135282

DHODH-IN-1	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-1 (compound 18d) is a potent *Dihydroorotate Dehydrogenase* (DHODH) inhibitor with an IC₅₀** of 25 nM. DHODH-IN-1 is an inhibitor of pyrimidine biosynthesis pathway.

HY-145985

CBR-3465

Bacterial Infection

CBR-3465 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.16 μM against Mtb.
HY-145986

CBR-6672

Bacterial Infection

CBR-6672 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.14 μM against Mtb.

CBR-3465	Bacterial	Infection
CBR-3465 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.16 μM against Mtb.

CBR-6672	Bacterial	Infection
CBR-6672 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.14 μM against Mtb.

HY-114702

M77976	PDHK	Metabolic Disease
M77976 is a specific ATP-competitive inhibitor of *PDK4 (pyruvate dehydrogenase* kinase isoforms 4), with an IC₅₀** of 648 μM. M77976 is potential for the research of obesity and diabetes.

HY-156270

SDH-IN-9	Bacterial	Infection
SDH-IN-9 (compound Ip) is a potent inhibitor of Succinate Dehydrogenase. SDH-IN-9 shows fungicidal activity against Fusarium graminearum Schw with the EC₅₀ of 0.93 μg/mL.

HY-139319

LDHA-IN-3 1 Publications Verification	Lactate Dehydrogenase	Cancer
LDHA-IN-3, as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC₅₀=145.2 nM). LDHA-IN-3 can be used for the research of cancer.

HY-W587754

Benzovindiflupyr	Fungal	Infection
Benzovindiflupyr is a succinate dehydrogenase inhibitor (SDHI). Benzovindiflupyr has high activity against S. sclerotiorum. Benzovindiflupyr can be used for the research of sclerotinia stem rot.

HY-116934

5-Pentadecylresorcinol Adipostatin A	Others	Cancer Infection
5-Pentadecylresorcinol (Adipostatin A) is a *glycerol-3-phosphate dehydrogenase* (GPDH) inhibitor with an IC₅₀** of 4.1 µM. Adipostatin A shows good larvicidal activity against Aedes aegypti.

HY-148570

PHGDH-IN-3	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-3 is an orally active *phosphoglycerate dehydrogenase* (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC₅₀** value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer.

HY-34154

4-(Dimethylamino)phenol	Others	Metabolic Disease
4-(Dimethylamino)phenol increases the extracellular lactate dehydrogenase (LDH) without markedly affecting gluconeogenesis. 4-(Dimethylamino)phenol cannot decreases the ATP content until the membrane becomes permeable to LDH.

HY-10250

Triciribine phosphate TCN-P	ATP Synthase	Metabolic Disease
Triciribine phosphate (TCN-P) inhibits amidophosphoribosyltransferase by an allosteric mechanism which affects the first committed step of de novo purine biosynthesis. Triciribine phosphate also inhibits IMP dehydrogenase which is the first committed step of guanosine nucleotide synthesis. Tricilibine phosphate does not affect ligase activity.

HY-135667

hDHODH-IN-7	Dihydroorotate Dehydrogenase Influenza Virus DNA/RNA Synthesis	Infection
DHODH-IN-9 (Compound 10k) is an azine-bearing analogue and is a human dihydroorotate dehydrogenase inhibitor. DHODH-IN-9 has antiviral effect with a pMIC₅₀ of 7.4.

HY-N8523

Vibralactone D	Others	Metabolic Disease
Vibralactone D (Compound 1) is a metabolite isolated and cultured from natural basidiomycetes Boreostereum vibrans. Vibralactone D shows weak inhibitory activity against isoenzymes of 11b-hydroxysteroid dehydrogenase (HSD) (IC₅₀ 85.7 μM).

HY-146801

PDHK-IN-3	PDHK	Cancer Metabolic Disease
PDHK-IN-3 (compound 7) is a potent PDHK (pyruvate dehydrogenase kinase) inhibitor, with IC₅₀ values of 0.21 and 1.54 μM for PDHK2 and PDHK4, respectively.

HY-126003

ALDH1A1-IN-2	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH1A1-IN-2 is a potent inhibitor of aldehyde dehydrogenase 1a1 (aldh1a1). Aldehyde dehydrogenases (ALDH) constitute a family of enzymes that play a critical role in oxidizing various cytotoxic xenogenic and biogenic aldehydes. ALDH1A1-IN-2 has the potential for the research of cancer, inflammation, or obesity (extracted from patent WO2019089626A1, compound 295).

HY-150753

RS6212	Lactate Dehydrogenase	Cancer
RS6212 is a specific LDH (lactate dehydrogenase) inhibitor with an IC₅₀ value of 12.03 μM . RS6212 inhibits tumor growth and exhibits potent anticancer activity in multiple cancer cell lines.

HY-145261

hDHODH-IN-8	Dihydroorotate Dehydrogenase	Inflammation/Immunology
hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC₅₀ of 16 nM. hDHODH-IN-8 has potent antiproliferative activity and excellent aqueous solubility. hDHODH-IN-8 has the potential for the research of tumor disease, especially lymphoma.

HY-B0876

Fomepizole 3 Publications Verification 4-Methylpyrazole	Cytochrome P450	Metabolic Disease
Fomepizole (4-Methylpyrazole) is a potent cytochrome P450 (CYP2E1) inhibitor. Fomepizole is a competitive inhibitor of the enzyme alcohol dehydrogenase. Fomepizole blocks further conversion of methanol and ethylene glycol to toxic metabolites. Fomepizole has the potential for an antidote for ethylene glycol or methanol poisoning.

HY-B0876A

Fomepizole hydrochloride 4-Methylpyrazole hydrochloride	Cytochrome P450	Metabolic Disease
Fomepizole (4-Methylpyrazole) hydrochloride is a potent and orally active cytochrome P450 (CYP2E1) inhibitor. Fomepizole hydrochloride is a competitive inhibitor of the enzyme alcohol dehydrogenase. Fomepizole hydrochloride blocks further conversion of methanol and ethylene glycol to toxic metabolites. Fomepizole hydrochloride has the potential for an antidote for ethylene glycol or methanol poisoning.

HY-134136A

Octanoyl coenzyme A lithium	Biochemical Assay Reagents	Cancer
Octanoyl coenzyme A lithium is a fatty acyl coenzyme A derivative. Octanoyl coenzyme A lithium can inhibit citrate synthase (CS) and glutamate dehydrogenase (GDH) with IC₅₀ values of 0.4-1.6 mM.

HY-147216A

AXKO-0046 dihydrochloride 1 Publications Verification	Lactate Dehydrogenase	Cancer Metabolic Disease Inflammation/Immunology
AXKO-0046 dihydrochloride, indole derivative, is an uncompetitive *Lactate dehydrogenase* B (LDHB) selective inhibitor. AXKO-0046 dihydrochloride has LDHB inhibitory activity with an EC₅₀** value of 42 nM. AXKO-0046 dihydrochloride can be used for the research of cancer metabolism.

HY-128888

(R,R)-GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
(R,R)-GSK321 is a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor with an IC₅₀ value of 120 nM. (R,R)-GSK321 as a mutant R132H IDH1 inhibitor, is an isomer of GSK321 with some wild-type cross reactivity.

HY-136882

TM-1	PDHK	Cancer
TM-1 is a potent inhibitor of *pyruvate dehydrogenase* kinase (PDHK1). TM-1 inhibits PDHK1 and PDHK2 with IC₅₀*s of 2.97 μM and 5.2 μM, respectively. TM-1 blocks pyruvate dehydrogenase* complex (PDHC) phosphorylation, and inhibits cell proliferation.

HY-149030

DHODH-IN-21	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-21 (compound 19) is an orally active selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 1.1 nM. DHODH-IN-21 has anticancer activity and can be used in studies of acute myeloid leukaemia (AML).

HY-136976

WST-1 1 Publications Verification	Fluorescent Dye
WST-1 is a kind of water-soluble tetrazolium salt. WST induces the intracellular mitochondrial dehydrogenase to conduct NADH-dependent enzyme digestion reaction, releasing the water-soluble methyl benzene product. WST-1 can be used for the detection of cell proliferation and cytotoxicity, via the determination of the light absorption value at 450 nm.

HY-148685

KM04416

Others Cancer

KM04416, an isothiazolone derivative, is a potent glycerol-3-phosphate dehydrogenase (GPD2) inhibitor. KM04416 significantly inhibits PNT1A cell proliferation.

HY-N12390

Alternaphenol B2	Isocitrate Dehydrogenase (IDH)	Cancer
Alternaphenol B2 is a selective IDH1 inhibitor from the coral-derived fungus Parengyodontium album SCSIO SX7W11. Alternaphenol B2 shows inhibitory activity against isocitrate dehydrogenase mutant R132H (IDH1m), with IC₅₀ values of 41.9 μM.

HY-113013

Hydroxypyruvic acid β-Hydroxypyruvic acid; 3-Hydroxypyruvic acid	Endogenous Metabolite	Metabolic Disease
Hydroxypyruvic acid (β-Hydroxypyruvic acid) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.

HY-76006

3-Hydroxybenzaldehyde M-Hydroxybenzaldehyde	Aldehyde Dehydrogenase (ALDH)	Cardiovascular Disease
3-Hydroxybenzaldehyde is a precursor compound for phenolic compounds, such as Protocatechualdehyde (HY-N0295). 3-Hydroxybenzaldehyde is a substrate of *aldehyde dehydrogenase* (ALDH)** in rats and humans (ALDH2). 3-Hydroxybenzaldehyde has vasculoprotective effects in vitro and in vivo.

HY-135841

CM10	Aldehyde Dehydrogenase (ALDH)	Cancer Metabolic Disease
CM10 is a potent and selective *aldehyde dehydrogenase* 1A (ALDH1A) family inhibitor, with IC₅₀**s of 1700, 740, and 640 nM for ALDH1A1, ALDH1A2, and ALDH1A3, respectively. CM10 does not inhibit any of the other ALDH family members. CM10 can regulate metabolism and has anti-cancer activity.

HY-B0421

Mycophenolic acid 4 Publications Verification Mycophenolate	Apoptosis Bacterial Fungal Endogenous Metabolite Antibiotic Flavivirus	Cancer Infection Inflammation/Immunology
Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC₅₀ of 0.24 µM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects.

HY-B0421A

Mycophenolic acid sodium Mycophenolate sodium	Apoptosis Bacterial Fungal Antibiotic Endogenous Metabolite Flavivirus	Cancer Infection Inflammation/Immunology
Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC₅₀ of 0.24 µM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects.

HY-18948

GSK321 1 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
GSK321 is a potent inhibitor of mutant *isocitrate dehydrogenase* 1 (IDH1) enzymes**. GSK321 has high inhibitory and selectivity for mutant IDH1 enzymes. GSK321 can be used for the research of acute myeloid leukemia.

HY-110159

(E/Z)-Teriflunomide (E/Z)-A77 1726	Dihydroorotate Dehydrogenase	Infection Inflammation/Immunology
(E/Z)-Teriflunomide ((E/Z)-A77 1726) is the active metabolite of Leflunomide (HY-B0083). Leflunomide is an immunomodulatory agent that may exert effects by inhibiting the mitochondrial enzyme *dihydroorotate dehydrogenase* (DHODH)**. Leflunomide can be used for the research of rheumatoid arthritis (RA).

HY-B0817

Pyridaben	Parasite	Infection
Pyridaben is a mitochondrial electron transport inhibitor (METI) acaricide that promotes the formation of damaging oxygen and nitrogen radicals. Pyridaben selectively inhibits complex I (NADH dehydrogenase) with an IC₅₀ value of 2.4 nM (assay sites: rat liver and bovine heart mitochondria). Pyridaben also significantly inhibits rat mitochondrial mtNOS function.

HY-148921

SDH-IN-2	Fungal	Infection
SDH-IN-2 is a potent *succinate dehydrogenase* (SDH) inhibitor with an IC₅₀ of 0.55 μg/mL. SDH-IN-2 is also an antifungal agent. SDH-IN-2 inhibits phytopathogenic fungia with average EC₅₀** values of 3.82-9.81 μg/mL for all the fungi. SDH-IN-2 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-113013A

Hydroxypyruvic acid lithium hydrate β-Hydroxypyruvic acid lithium hydrate; 3-Hydroxypyruvic acid lithium hydrate	Endogenous Metabolite	Metabolic Disease
Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.

HY-17462

Adrenosterone (+)-Adrenosterone	Androgen Receptor Endogenous Metabolite	Cancer Endocrinology
Adrenosterone ((+)-Adrenosterone) is a competitive **hydroxysteroid (11-beta) dehydrogenase 1 (HSD11β1)** inhibitor. Adrenosterone is a steroid hormone with weak androgenic effect. Adrenosterone is a dietary supplement that can decrease fat and increase muscle mass. Adrenosterone acts as a suppressor of metastatic progression of human cancer cells.

HY-156442

MEDS433	Lactate Dehydrogenase	Infection
MEDS433 is a potent inhibitor of *human dihydroorotate dehydrogenase* (hDHODH) with an IC₅₀** of 1.2 nM. MEDS433 exerts a potent antiviral activity against RSV-A and RSV-B in the one-digit nanomolar range. MEDS433 induces the expression of antiviral proteins encoded by interferon stimulated genes (ISGs) able to reduce RSV replication.

HY-148396

UCK2 Inhibitor-3	DNA/RNA Synthesis	Cancer Infection
UCK2 Inhibitor-3 is a non-competitive inhibitor of uridine-cytidine kinase 2 (UCK2, a pyrimidine salvage enzyme) with an IC₅₀ value of 16.6 μM. UCK2 can replace dihydroorotate dehydrogenase (DHODH), in a certain extent, in infected or rapidly dividing cells to continue efficient uridine salvage. UCK2 Inhibitor-3 also inhibits DNA polymerase eta and kappa with IC₅₀s of 56 μM and 16 μM.

HY-10617D

Rucaparib acetate AG014699 acetate; PF-01367338 acetate	PARP	Cancer
Rucaparib (AG014699) acetate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib acetate is a modest *hexose-6-phosphate dehydrogenase* (H6PD)** inhibitor. Rucaparib acetate has the potential for castration-resistant prostate cancer (CRPC) research.

HY-10617B

Rucaparib hydrochloride AG014699 hydrochloride; PF-01367338 hydrochloride	PARP	Cancer
Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest *hexose-6-phosphate dehydrogenase* (H6PD)** inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research.

HY-10617C

Rucaparib tartrate AG-014699 tartrate; PF-01367338 tartrate	PARP	Cancer
Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib tartrate is a modest *hexose-6-phosphate dehydrogenase* (H6PD)** inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research.

HY-B0421S2

Mycophenolic acid-13C17 Mycophenolate-¹³C₁₇	Isotope-Labeled Compounds Flavivirus	Cancer
Mycophenolic acid-13C17 (Mycophenolate-13C17) is the 13C labeled Mycophenolic acid (HY-B0421). Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 μM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects.

HY-W107464

G6PDi-1	PDI	Metabolic Disease Inflammation/Immunology
G6PDi-1 is a reversible and non-competitive *glucose-6-phosphate dehydrogenase* (G6PD) inhibitor with an IC₅₀** of 0.07 μM. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells.

HY-113165

Isobutyryl-L-carnitine

Endogenous Metabolite Metabolic Disease

Isobutyryl-L-carnitine is a product of the acyl-CoA dehydrogenases.
HY-W007330

2-Bromoacetamide

Others Metabolic Disease

2-Bromoacetamide can inactivate alcohol dehydrogenase.

HY-125954A

Uridine diphosphate glucuronic acid ammonium UDP-α-D-glucuronic acid ammonium	Endogenous Metabolite	Metabolic Disease
Uridine diphosphate glucuronic acid (UDP-GlcA) ammonium is a cofactor that is formed by the catalytic activity of UDP-glucose dehydrogenase. Uridine diphosphate glucuronic acid (ammonium) is a central precursor in sugar nucleotide biosynthesis and common substrate for C4-epimerases and decarboxylases releasing UDP-galacturonic acid (UDP-GalA) and UDP-pentose products, respectively. Uridine diphosphate glucuronic acid (ammonium), as a glucuronic acid donor, can be used for for the research of the conjugation of bilirubin in the endoplasmic recticulum.

HY-113076

Thiamine pyrophosphate	Endogenous Metabolite	Metabolic Disease
Thiamine pyrophosphate is the coenzyme form of Vitamin B1 and is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex.

HY-113165AS

Isobutyryl-L-carnitine-d3 chloride	Endogenous Metabolite	Metabolic Disease
Isobutyryl-L-carnitine-d₃ (chloride) is the deuterium labeled Isobutyryl-L-carnitine chloride. Isobutyryl-L-carnitine chloride is a product of the acyl-CoA dehydrogenases[1].

HY-14908

Vidofludimus 4sc-101; SC12267	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus is an orally active inhibitor for *dihydroorotate dehydrogenase* (DHODH) and also is a novel modulator for farnesoid X receptor (FXR)**. Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR.

HY-W012530S

Phenylpyruvic acid-13C6 sodium	Isotope-Labeled Compounds Endogenous Metabolite	Others
Phenylpyruvic acid-¹³C₆ sodium is the ¹³C-labeled Phenylpyruvic acid. Phenylpyruvic acid is used in the synthesis of 3-phenyllactic acid (PLA) by lactate dehydrogenase.

HY-113076S

Thiamine pyrophosphate-d3	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Thiamine pyrophosphate-d₃ is the deuterium labeled Thiamine pyrophosphate. Thiamine pyrophosphate is the coenzyme form of Vitamin B1 and is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex.

HY-N1177

Taraxerone	Aldehyde Dehydrogenase (ALDH)	Inflammation/Immunology
Taraxerone is isolated from Sedum sarmentosum. Taraxerone enhances effects on alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) activities with EC₅₀ values of 512.42 and 500.16 μM, respectively.

HY-148617

ALDH2 modulator 1	Aldehyde Dehydrogenase (ALDH)	Metabolic Disease
ALDH2 modulator 1 is a potent and orally active *aldehyde dehydrogenase-2 (ALDH2)* modulator. ALDH2 modulator 1 reduces blood alcohol levels in mice.

HY-14908A

Vidofludimus hemicalcium 4sc-101 hemicalcium; SC12267 hemicalcium	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for *dihydroorotate dehydrogenase* (DHODH) and also is a novel modulator for farnesoid X receptor (FXR)**. Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR.

HY-129545

DS-1001b 1 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
DS-1001b is a mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor extracted from patent WO2016052697A1, Example 168, and has antitumor activity.

HY-148682

18β-Glycyrrhetyl-3-O-sulfate Glycyrrhetic acid 3-O-hydrogen sulfate	11β-HSD Drug Metabolite	Metabolic Disease Inflammation/Immunology
18β-Glycyrrhetyl-3-O-sulfate (Glycyrrhetic acid 3-O-(hydrogen sulfate)) is a potent type 2 11β-hydroxysteroid dehydrogenase (11β-HSD2) inhibitor with an IC₅₀ of 0.10 µM using rat kidney microsome. 18β-Glycyrrhetyl-3-O-sulfate is the major metabolite of Glycyrrhetinic acid (GA). 18β-Glycyrrhetyl-3-O-sulfate is the substrate of organic anion transporter (OAT) 1 and OAT3. 18β-Glycyrrhetyl-3-O-sulfate has anti-inflammatory effects and has the potential for pseudohyperaldosteronism research.

HY-W008129

H-D-cis-Hyp-OH	Endogenous Metabolite	Metabolic Disease
cis-4-Hydroxy-D-proline is a precursor of conformationally restricted PNA adenine monomer. cis-4-Hydroxy-D-proline can be used to study the specificity and kinetics of D-alanine dehydrogenase.

HY-15920

INT 1 Publications Verification Iodonitrotetrazolium chloride; p-Iodonitrotetrazolium Violet	Biochemical Assay Reagents	Others
INT(Iodonitrotetrazolium chloride) is used in various dehydrogenase colorimetric analysis of the electron acceptor.

HY-W012530

Phenylpyruvic acid

Endogenous Metabolite Others

Phenylpyruvic acid is used in the synthesis of 3-phenyllactic acid (PLA) by lactate dehydrogenase.

HY-110217

BMS-566419	Others	Others
BMS-566419 is an acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase (IMPDH). Inosine monophosphate dehydrogenase (IMPDH) is a key enzyme in the de novo synthesis of guanosine nucleotides. BMS-566419 has clinical utility for the research of transplant rejection.

HY-N2498

Glomeratose A

Lactate Dehydrogenase Others

Glomeratose A is a lactate dehydrogenase inhibitor, isolated from Polygala tenuifolia.
HY-139851

Fungicide5

Fungal Infection

Fungicide5 is a fungicide candidate targeting succinate dehydrogenase (K_i = 0.095 μM).
HY-101966

NCT-503

10+ Cited Publications

Phosphoglycerate Dehydrogenase (PHGDH) Cancer

NCT-503 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC₅₀ of 2.5 µM.

HY-112645

BAY-2402234 4 Publications Verification	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
BAY-2402234 is a selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies.

HY-149653

SDH-IN-10

Fungal Infection

SDH-IN-10 is a potent succinate dehydrogenase inhibitor (SDHI) with antifungal effects.

HY-132606A

Nedosiran sodium DCR-PHXC sodium	Lactate Dehydrogenase	Others
Nedosiran sodium is a GalNAc-dsRNA conjugate designed to inhibit production of the hepatic lactate dehydrogenase (LDH) enzyme.

HY-100020

BAY-1436032

3 Publications Verification

Isocitrate Dehydrogenase (IDH) Cancer

BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.

HY-B0083

Leflunomide 5+ Cited Publications HWA486; RS-34821; SU101	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial	Cancer
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-120496

Clofutriben

ASP3662
11β-HSD Metabolic Disease

Clofutriben (ASP3662) is a 11β-hydroxysteroid dehydrogenase type 1 inhibitor.
HY-146317

P1788

Dihydroorotate Dehydrogenase DNA/RNA Synthesis Cancer Inflammation/Immunology

P1788 is a dihydroorotate dehydrogenase (DHODH) inhibitor. P1788 induces DNA damage.

HY-18768

NCT-501 4 Publications Verification	Aldehyde Dehydrogenase (ALDH)	Cancer
NCT-501 is a potent and selective theophylline-based inhibitor of *aldehyde dehydrogenase* 1A1 (ALDH1A1), inhibits hALDH1A1 with IC₅₀** of 40 nM, typically shows better selectivity over other ALDH isozymes and other dehydrogenases (hALDH1B1, hALDH3A1, and hALDH2, IC₅₀ >57 μM).

HY-100742B

(S)-GNE-140

Lactate Dehydrogenase Cancer

(S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A (LDHA).

HY-13986

Merimepodib 2 Publications Verification VX-497; MMPD	Flavivirus HBV HCV	Infection
Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.

HY-139189

DHODH-IN-16

Dihydroorotate Dehydrogenase DNA/RNA Synthesis Cancer

DHODH-IN-16 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.396 nM for human DHODH.

HY-77521

Dabigatran ethyl ester hydrochloride 1 Publications Verification	Thrombin	Cardiovascular Disease
Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase (NQO2) with an IC₅₀ value of 0.8 μM and a thrombin inhibitor.

HY-139839

Y12196

Fungal Infection

Y12196 is a novel succinate dehydrogenase inhibitor (SDHI) which exhibits strong fungicidal activity against F. graminearum.
HY-149825

MTHFD2-IN-1

Methylenetetrahydrofolate Dehydrogenase (MTHFD) Cancer

MTHFD2-IN-1 (compound 12) is a potent methylenetetrahydrofolate dehydrogenase (MTHFD2) inhibitor.

HY-W014787

Decanedioic acid	Endogenous Metabolite	Metabolic Disease
Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency.

HY-149826

MTHFD2-IN-2

Methylenetetrahydrofolate Dehydrogenase (MTHFD) Cancer

MTHFD2-IN-2 (compound 13) is a potent methylenetetrahydrofolate dehydrogenase (MTHFD2) inhibitor.
HY-149827

MTHFD2-IN-3

Methylenetetrahydrofolate Dehydrogenase (MTHFD) Cancer

MTHFD2-IN-3 (compound 10) is a potent methylenetetrahydrofolate dehydrogenase (MTHFD2) inhibitor.

HY-19801

CVT-10216 1 Publications Verification	Aldehyde Dehydrogenase (ALDH)	Neurological Disease
CVT-10216 is a highly selective, reversible *aldehyde dehydrogenase-2 (ALDH-2)* inhibitor with an IC₅₀ of 29 nM. CVT-10216 also has inhibitory effect of ALDH-1 with an IC₅₀ of 1.3 μM. CVT-10216 can reduce excessive alcohol drinking in alcohol-preferring rats and exhibit anxiolytic effects.

HY-18768A

NCT-501 hydrochloride	Aldehyde Dehydrogenase (ALDH)	Cancer
NCT-501 hydrochloride is a potent and selective theophylline-based inhibitor of *aldehyde dehydrogenase* 1A1 (ALDH1A1), inhibits hALDH1A1 with IC₅₀** of 40 nM, typically shows better selectivity over other ALDH isozymes and other dehydrogenases (hALDH1B1, hALDH3A1, and hALDH2, IC₅₀ >57 μM).

HY-105286

BI-135585	11β-HSD	Metabolic Disease
BI-135585 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor with an IC₅₀ of 13 nM. BI-135585 exhibits >1000-fold selectivity over other hydroxysteroid dehydrogenases. BI-135585 can be used for type 2 diabetes research.

HY-107030

Nitrefazole EMD-15700	Aldehyde Dehydrogenase (ALDH)	Metabolic Disease
Nitrefazole is a 4-nitroimidazole derivative with strong and long lasting inhibition of *aldehyde dehydrogenase* (ALDH)**, an enzyme involved in the metabolism of alcohol.

HY-157153

hDHODH-IN-14	DNA/RNA Synthesis Dihydroorotate Dehydrogenase	Inflammation/Immunology
hDHODH-IN-14 (compound 14) is a *human dihydroorotate dehydrogenase* (hDHODH) inhibitor with an IC₅₀** of 0.469 μM.

HY-N6736

K-252c	PKC Bacterial Apoptosis	Cancer Infection
K-252c, a staurosporine analog isolated from Nocardiopsis sp., is a cell-permeable PKC inhibitor, with an IC₅₀ of 2.45 µM. K-252c induces apoptosis in human chronic myelogenous leukemia cancer cells. K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase.

HY-100681

GSK2837808A 15+ Cited Publications	Lactate Dehydrogenase	Cancer
GSK2837808A is a potent and selective *lactate dehydrogenase* A (LDHA) inhibitor with IC₅₀**s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.

HY-135676

DHODH-IN-12	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-12 (Compound 12b) is a Leflunomide derivative and a weak *dihydroorotate dehydrogenase* (DHODH) inhibitor with a pK_a** of 5.07.

HY-118382

SCH-451659

17β-HSD Cancer

SCH-451659 is an inhibitor of 17β-hydroxysteroid dehydrogenases (17β-HSDs) for cancer research.
HY-103096

R162

5+ Cited Publications

Others Cancer

R162 is a potent inhibitor of glutamate dehydrogenase 1 (GDH1/GLUD1), with anti-cancer properties.
HY-18968

LDHA-IN-4

Lactate Dehydrogenase Cancer

AZ-33 is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC₅₀ of 0.5 μM and a K_d of 0.093 μM.
HY-119459

Fluopyram

Fungal Infection

Fluopyram is a succinate dehydrogenase inhibitor fungicide, inhibits the growth of F. virguliforme isolates with mean EC₅₀ of 3.35 µg/mL.

HY-135675

DHODH-IN-11	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-11 (Compound 14b) is a Leflunomide derivative and a weak *dihydroorotate dehydrogenase* (DHODH) inhibitor with a pK_a** of 5.03.

HY-110294

CM037

A37
Aldehyde Dehydrogenase (ALDH) Cancer

CM037 is a selective inhibitor of ALDH1A1 (aldehyde dehydrogenase 1A1) with an IC₅₀ of 4.6 µM.

HY-N2597

Prunetin	Aldehyde Dehydrogenase (ALDH)	Inflammation/Immunology
Prunetin, an O-methylated isoflavone, possesses anti-inflammatory activity. Prunetin is a potent human aldehyde dehydrogenases inhibitor.

HY-124062

TAS-114 2 Publications Verification	Others	Cancer
TAS-114 is an orally active dual *dUTPase/dihydropyrimidine dehydrogenase* (DPD)** inhibitor, can improving the therapeutic efficacy of fluoropyrimidine.

HY-112278

NCT-506

Aldehyde Dehydrogenase (ALDH) Cancer

NCT-506 is an orally bioavailable aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with an IC₅₀ of 7 nM.

HY-154865

Anticancer agent 121	Lactate Dehydrogenase	Cancer
Anticancer agent 121, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research.

HY-113451

3-Hydroxysebacic acid	Endogenous Metabolite	Metabolic Disease
3-Hydroxysebacic acid is an endogenous metabolite present in Urine that can be used for the research of Medium Chain Acyl Co A Dehydrogenase Deficiency.

HY-122373

Coprine	Others	Others
Coprine is a mycotoxin isolated from Coprinopsis atramentaria. Coprine is an acetaldehyde dehydrogenase inhibitor that causes the buildup of acetaldehyde, causing the alcohol flushing reaction.

HY-154866

Anticancer agent 122	Lactate Dehydrogenase	Cancer
Anticancer agent 122, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research.

HY-111108

LDH-IN-1 1 Publications Verification	Lactate Dehydrogenase	Cancer
LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC₅₀s of 32 and 27 nM for LDHA and LDHB, respectively.

HY-113304

(S)-3,4-Dihydroxybutyric acid	Endogenous Metabolite	Metabolic Disease
(S)-3,4-Dihydroxybutyric acid is a normal human urinary metabolite that is excreted in increased concentration in patients with succinic semialdehyde dehydrogenase (SSADH) deficiency.

HY-W001941

D-Cystine

Others Others

D-Cystine is the D-enantiomer of L-Cystine. D-Cystine inhibits L-aspartate-β-semialdehyde dehydrogenase (ASADH) from Escherichia coli.
HY-120338

RYL-552

Mitochondrial Metabolism Parasite Infection

RYL-552, a mitochondrial electron transport chain (ETC) inhibitor, is a P. falciparum NADH dehydrogenase 2 (PfNDH2) inhibtor.

HY-113128

sn-Glycerol 3-phosphate	Endogenous Metabolite	Others
sn-Glycerol 3-phosphate is produced by cytosolic glycerol 3-phosphate dehydrogenase pathway through the reduction of dihydroxyacetone phosphate using NADH formed during glycolysis.

HY-12688

Succinyl phosphonate	Endogenous Metabolite Reactive Oxygen Species	Neurological Disease
Succinyl phosphonate is an α-ketoglutarate dehydrogenase (KGDHC) inhibitor, effective inhibits (KGDHC) in muscle, bacterial, brain, and cultured human fibroblasts. Succinyl phosphonate trisodium salt is an 2-oxoglutarate dehydrogenase (OGDH) inhibitor, impairs viability of cancer cells in a cell-specific metabolism-dependent manner. Succinyl phosphonate trisodium salt inhibits the glutamate-induced ROS production in glutamate-stimulated hippocampal neurons in situ.

HY-N7961

(E/Z)-Ginkgolic acid C17:2	Dihydroorotate Dehydrogenase	Others
(E/Z)-Ginkgolic acid C17:2, isolated from Ginkgo biloba, can bind with human *dihydroorotate dehydrogenase* (DHODH)** tightly.

HY-18055

BVT-14225

1 Publications Verification

11β-HSD Metabolic Disease

BVT-14225 is a selective 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with an IC₅₀ of 52 nM.

HY-113128A

sn-Glycerol 3-phosphate lithium	Endogenous Metabolite	Metabolic Disease
sn-Glycerol 3-phosphate lithium is produced by cytosolic glycerol 3-phosphate dehydrogenase pathway through the reduction of dihydroxyacetone phosphate using NADH formed during glycolysis.

HY-18053

AZD 4017

11β-HSD Metabolic Disease

AZD 4017 is a potent, selective 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) inhibitor, with an IC₅₀ of 7 nM.

HY-113043

Galactonic acid	Endogenous Metabolite	Others
Galactonic acid is a sugar acid that is a metabolic breakdown product of galactose. Galactose dehydrogenase is responsible for converting galactose to galactonolactone, which then spontaneously or enzymatically converts to galactonic acid.

HY-113166

Dodecanoylcarnitine	Endogenous Metabolite	Metabolic Disease
Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease.

HY-113128B

sn-Glycerol 3-phosphate biscyclohexylammonium salt	Endogenous Metabolite	Metabolic Disease
sn-Glycerol 3-phosphate biscyclohexylammonium salt is produced by cytosolic glycerol 3-phosphate dehydrogenase pathway through the reduction of dihydroxyacetone phosphate using NADH formed during glycolysis.

HY-D0007

Blue Tetrazolium Tetrazolium blue	Fluorescent Dye	Others
Blue Tetrazolium (Tetrazolium blue), as a blue dye for microbial research, can be reduced into blue tetrazolium formazan (BTF). Blue Tetrazolium can be used to determine the activity of succinate dehydrogenase (SDH) in yeast strains, which has been reduced as a substrate. Use DMSO to extract BTF from cells, and test absorption spectrum of BTF. The BTF shows a wide wavelength range of 480-600 nm with maximal absorbance seen at 540 nm. Blue Tetrazolium, combines with succinate dehydrogenase (SDH).

HY-12688A

Succinyl phosphonate trisodium salt 5+ Cited Publications	Endogenous Metabolite Reactive Oxygen Species	Cancer Metabolic Disease Neurological Disease
Succinyl phosphonate trisodium salt is an α-ketoglutarate dehydrogenase (KGDHC) inhibitor, effective inhibits (KGDHC) in muscle, bacterial, brain, and cultured human fibroblasts. Succinyl phosphonate trisodium salt is an 2-oxoglutarate dehydrogenase (OGDH) inhibitor, impairs viability of cancer cells in a cell-specific metabolism-dependent manner. Succinyl phosphonate trisodium salt inhibits the glutamate-induced ROS production in glutamate-stimulated hippocampal neurons in situ.

HY-17469

Gimeracil 2 Publications Verification Gimestat	Others	Cancer
Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of *DPYD (dihydropyrimidine dehydrogenase, DPD)*.

HY-B2004

Thifluzamide	Fungal	Infection
Thifluzamide, a broad-spectrum succinate dehydrogenase inhibitor (SDHI) fungicide, has been widely used in the controlling of a variety of fungal diseases in rice fields.

HY-122577

EN40

Aldehyde Dehydrogenase (ALDH) Cancer

EN40 is a potent, selective aldehyde dehydrogenase 3A1 (ALDH3A1) inhibitor as a covalent ligand, exhibits an IC₅₀ value of 2 uM

HY-N7114A

Chloramphenicol succinate sodium 1 Publications Verification	Bacterial Antibiotic	Metabolic Disease Infection
Chloramphenicol succinate sodium is a proagent of Chloramphenicol, with Haemotoxicity. Chloramphenicol succinate is a competitive substrate and inhibitor of succinate dehydrogenase (SDH) that is the possible reason for its toxicity.

HY-135570

hDHODH-IN-3	DNA/RNA Synthesis Dihydroorotate Dehydrogenase Influenza Virus	Infection
hDHODH-IN-3 (compound 21d) is a *human dihydroorotate dehydrogenase* (HsDHODH) inhibitor, inhibits measles virus replication with a pMIC₅₀** value of 8.6.

HY-113304A

(S)-3,4-Dihydroxybutyric acid lithium hydrate	Endogenous Metabolite	Metabolic Disease
(S)-3,4-Dihydroxybutyric acid (lithium hydrate) is a normal human urinary metabolite that is excreted in increased concentration in patients with succinic semialdehyde dehydrogenase (SSADH) deficiency.

HY-135664

hDHODH-IN-5	DNA/RNA Synthesis Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-7 is a human *dihydroorotate dehydrogenase* (DHODH) inhibitor, with an IC₅₀** of 0.91 μM. DHODH-IN-7 induces differentiation in acute myeloid leukemia.

HY-145326

Antibacterial agent 67	Fungal	Others
Antibacterial agent 67 (IC₅₀ = 0.03 μM) has a great enzyme-inhibiting activity increase toward succinate dehydrogenase in comparison with fluxapyroxad (IC₅₀ = 4.40 μM).

HY-W040073

Nifurtimox	Parasite Lactate Dehydrogenase	Cancer Infection
Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).

HY-N2337

11beta-Hydroxyprogesterone 2 Publications Verification 11β-Hydroxyprogesterone	Endogenous Metabolite	Cardiovascular Disease
11beta-Hydroxyprogesterone is a potent inhibitors of 11β-Hydroxysteroid dehydrogenase; also activates human mineralocorticoid receptor in COS-7 cells with an ED₅₀ of 10 nM.

HY-113347

cis-5-Tetradecenoic acid	Endogenous Metabolite	Others
cis-5-Tetradecenoic acid is an endogenous metabolite present in Blood that can be used for the research of Long Chain 3 Hydroxyacyl CoA Dehydrogenase Deficiency.

HY-147280

Misetionamide GP-2250	Apoptosis	Cancer
Misetionamide is an orally oxathiazin-like compound. Misetionamide is a *glyceraldehyde-3-phosphate dehydrogenase* (GAPDH)** inhibitor with antineoplastic activity. Misetionamide can be used for the research of cancer.

HY-129630

Tetrahydrocortisol	Endogenous Metabolite	Metabolic Disease
Tetrahydrocortisol is cortisol metabolite. The urinary Tetrahydrocortisol/Tetrahydrocortisone ratio decreases with increasing 11β-hydroxysteroid dehydrogenase (11β-HSD) activity.

HY-106371

Siccanin	Antibiotic Fungal	Infection
Siccanin is a succinate dehydrogenase (SDH) inhibitor (IC₅₀=0.9 μM) with species-selective activity. Siccanin also is a antibiotic against pathogenic fungi.

HY-18717

Mutant IDH1-IN-2 2 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.

HY-100742

GNE-140 racemate 4 Publications Verification	Lactate Dehydrogenase	Cancer
GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent *lactate dehydrogenase* A (LDHA)** inhibitor.

HY-W005629

Leelamine	Cannabinoid Receptor PDHK	Cancer
Leelamine is a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine also inhibits *pyruvate dehydrogenase* kinases (PDKs)**. Leelamine exhibits anti-tumor activity.

HY-132170

DSM502	Dihydroorotate Dehydrogenase Parasite	Infection
DSM502 is a pyrrole-based *Dihydroorotate Dehydrogenase* (DHODH)** inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs.

HY-137463

AG-636	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
AG-636 is a potent, reversible, selective and orally active *dihydroorotate dehydrogenase* (DHODH) inhibitor with an IC₅₀** of 17 nM. AG-636 has strong anticancer effects.

HY-B0199A

Mycophenolate mofetil hydrochloride RS 61443 hydrochloride; TM-MMF hydrochloride	Endogenous Metabolite Bacterial	Cancer
Mycophenolate mofetil (RS 61443) hydrochloride is a immunosuppressant, a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPD) type I/II with IC₅₀s of 39 nM and 27 nM, respectively.

HY-Y1787

Dimethyl malonate	Apoptosis	Neurological Disease
Dimethyl malonate is a competitive inhibitor of succinate dehydrogenase (SDH). Dimethyl malonate is able to cross the blood-brain barrier and hydrolyse to malonate. Dimethyl malonate reduces neuronal apoptosis.

HY-131943

DS44960156	Methylenetetrahydrofolate Dehydrogenase (MTHFD)	Others
DS44960156 is a selective *Methylenetetrahydrofolate dehydrogenase* 2 (MTHFD2) inhibitor, with IC₅₀** values of 1.6 μM and >30 μM for MTHFD2 and MTHFD1, respectively.

HY-149642

hDHODH-IN-13	Dihydroorotate Dehydrogenase	Others
hDHODH-IN-13 (compound w2) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC₅₀ value of 173.4 nM. hDHODH-IN-13 can be used in the research of IBD.

HY-D0714

Tetrazolium Red 2 Publications Verification 2,3,5-Triphenyltetrazolium chloride; TPTZ; TTC	Biochemical Assay Reagents	Others
Tetrazolium Red(2,3,5-Triphenyltetrazolium chloride; TPTZ) is used to visualize dehydrogenase enzyme activity; initially the tetrazolium solution is colorless but changes to red when it comes into contact with hydrogen.

HY-W013032A

Oxamic acid sodium 2 Publications Verification Sodium oxamate	Lactate Dehydrogenase Apoptosis	Cancer
Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis.

HY-128578

KPLH1130	PDHK	Metabolic Disease Inflammation/Immunology
KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses. KPLH1130 improves glucose tolerance in HFD-fed mice.

HY-113375

D-Ribofuranose D-Ribose	Endogenous Metabolite	Cardiovascular Disease
D-Ribofuranose (D-Ribose) is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Ribose 5 Phosphate Isomerase Deficiency and Medium Chain Acyl Co A Dehydrogenase Deficiency.

HY-135654

hDHODH-IN-2	DNA/RNA Synthesis Dihydroorotate Dehydrogenase	Inflammation/Immunology
hDHODH-IN-2 is an analogue of the active metabolite of Leflunomide. hDHODH-IN-2 is a *human dihydroorotate dehydrogenase* (hDHODH)** inhibitor. hDHODH-IN-1 has anti-inflammatory activity.

HY-107977

IDH1 Inhibitor 3

Isocitrate Dehydrogenase (IDH) Cancer

IDH1 Inhibitor 3 (compound 6f) is a mutant isocitric dehydrogenase 1 (IDH1) inhibitor, with an IC₅₀ of 45 nM for IDH1^R132H.

HY-W017522

Adipic acid	Endogenous Metabolite	Metabolic Disease
Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism.

HY-135648

PfDHODH-IN-1	Parasite Lactate Dehydrogenase DNA/RNA Synthesis	Infection
PfDHODH-IN-1 is an analogue of the active metabolite of Leflunomide. PfDHODH-IN-1 is a Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor. PfDHODH-IN-1 has antimalarial activity.

HY-123269

PKUMDL-WQ-2101	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PKUMDL-WQ-2101 is a non-NAD⁺-competing allosteric *phosphoglycerate dehydrogenase* (PHGDH) inhibitor with an IC₅₀** of 34.8 μM. PKUMDL-WQ-2101 exhibits antitumor activity.

HY-W012875

3-Nitropropanoic acid β-Nitropropionic acid; Bovinocidin	Bacterial Apoptosis	Infection Metabolic Disease
3-Nitropropanoic acid (β-Nitropropionic acid) is an irreversible inhibitor of succinate dehydrogenase. 3-Nitropropanoic acid exhibits potent antimycobacterial activity with a MIC value of 3.3 μM.

HY-D0845

Nitrosoglutathione GSNO; RVC-588; S-Nitroso-L-glutathione	Angiotensin Receptor	Inflammation/Immunology Cardiovascular Disease
Nitrosoglutathione (GSNO), a exogenous NO donor and a substrate for rat alcohol dehydrogenase class III isoenzyme, inhibits cerebrovascular angiotensin II-dependent and -independent AT1 receptor responses.

HY-120924

BRD9185	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite	Infection
BRD9185 is a *Dihydroorotate dehydrogenase* (DHODH) inhibitor, with an EC₅₀** of 16 nM against multidrug-resistant blood-stage parasites in vitro and is curative after just three doses in a P. berghei mouse model.

HY-N7114

Chloramphenicol succinate	Antibiotic Bacterial	Infection Metabolic Disease
Chloramphenicol succinate is a proagent of Chloramphenicol, with Haemotoxicity. Chloramphenicol succinate also is an antibiotic. Chloramphenicol succinate is a competitive substrate and inhibitor of succinate dehydrogenase (SDH) that is the possible reason for its toxicity.

HY-113212

Ursocholic acid	Endogenous Metabolite	Metabolic Disease
Ursocholic acid, a bile acid found predominantly in bile of mammals, is transformed into deoxycholic acid by the intestinal microflora in mice. Ursodeoxycholic acid is an inhibitor of 7α-hydroxysteroid dehydrogenase and hepatocyte nuclear factor 1α.

HY-136498

T-705RMP	Drug Metabolite	Infection
T-705RMP, a phosphorylated metabolite of T-705, exhibits a very weak inhibitory effect on the IMP dehydrogenase (IMPDH) activities of the host cells, with an IC₅₀ of 601 μM.

HY-N3115

Palbinone	Others	Inflammation/Immunology
Palbinone is a terpenoid isolated from the roots of Paeonia albiflora Pallas, potently inhibits *3α-hydroxysteroid* dehydrogenase (3α-HSD), with an IC₅₀** of 46 nM. Anti-inflammatory activity.

HY-101943

LY 345899 4 Publications Verification	Methylenetetrahydrofolate Dehydrogenase (MTHFD)	Cancer
LY 345899 is a Folate analog and is a methylene tetrahydrofolate dehydrogenase (MTHFD1; DC301) and MTHFD2 inbhibitor with IC₅₀ values of 96 nM and 663 nM, respectively and a K_i of 18 nM for MTHFD1.

HY-117240

NCT-502 5 Publications Verification	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
NCT-502 is a human phosphoglycerate dehydrogenase (PHGDH) inhibitor, cytotoxic to PHGDH-dependent cancer cells, and reduces glucose-derived serine production, with an IC₅₀ of 3.7 μM against PHGDH.

HY-16082

AZD7545 1 Publications Verification	PDHK	Metabolic Disease
AZD7545 is a potent, competitive, selective PDHK2 (pyruvate dehydrogenase kinase 2) inhibitor with IC₅₀s of 36.8 nM, 6.4 nM for PDHK1 and PDHK2, respectively.

HY-155700

SDH-IN-6	Fungal	Infection
SDH-IN-6 (compound 6i) is a potent *succinate dehydrogenase* (SDH)** inhibitor. SDH-IN-6 has antifungal activity against Valsa mali with an EC₅₀ value of 1.77 mg/L.

HY-W012926S1

Dihydrouracil-d4 5,6-Dihydrouracil-d4	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Dihydrouracil-d4 is the deuterium labeled Dihydrouracil. Dihydrouracil (HY-W012926), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient.

HY-15925

Nitro blue tetrazolium chloride 3 Publications Verification NBT	Fluorescent Dye	Others
Nitro blue tetrazolium chloride (NBT) is a substrate for dehydrogenases; is used with the alkaline phosphatase substrate 5-Bromo-4-Chloro-3-Indolyl Phosphate (BCIP) in western blotting and immunohistological staining procedures.

HY-13986A

(R)-Merimepodib (R)-VX-497; (R)-MMPD	Others	Infection
(R)-Merimepodib is the inactive isomer of Merimepodib (HY-13986), and can be used as an experimental control. Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.

HY-W016645

4-Diethylaminobenzaldehyde 1 Publications Verification	Aldehyde Dehydrogenase (ALDH)	Cancer
4-Diethylaminobenzaldehyde is a reversible *aldehyde dehydrogenases* (ALDHs) inhibitor, with a K_i** of 4 nM for ALDH1. 4-Diethylaminobenzaldehyde displays potent anti-androgenic effect (IC₅₀= 1.71μM).

HY-149031

DHODH-IN-22	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-22 is a potent, selective and orally active *dihydroorotate dehydrogenase* (DHODH) inhibitor with an IC₅₀** value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML).

HY-W014787S

Decanedioic acid-d4	Endogenous Metabolite	Metabolic Disease
Decanedioic acid-d₄ is the deuterium labeled Decanedioic acid[1]. Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency[2].

HY-108012

ME1111	Fungal	Infection
ME1111 is an antifungal agent that is active against dermatophytes. ME1111 is an inhibitor of the succinate dehydrogenase of Trichophyton species. ME1111 has an excellent ability to penetrate human nails and is used for onychomycosis research.

HY-132171

DSM705	Dihydroorotate Dehydrogenase Parasite	Infection
DSM705 is a pyrrole-based *Dihydroorotate Dehydrogenase* (DHODH)** inhibitor. DSM705 exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs. DSM705 is a potent antimalarial compound.

HY-128787

hDHODH-IN-4	Influenza Virus DNA/RNA Synthesis Dihydroorotate Dehydrogenase	Infection
hDHODH-IN-4 is a potent human *dihydroorotate dehydrogenase* (DHODH) inhibitor, with a pIC₅₀ of 7.8 for human recombinant DHODH. hDHODH-IN-4 inhibits measles virus replication, with a pMIC₅₀** of 8.8.

HY-W014787S1

Decanedioic acid-d16	Endogenous Metabolite	Metabolic Disease
Decanedioic acid-d₁₆ is the deuterium labeled Decanedioic acid[1]. Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency[2].

HY-100742A

(R)-GNE-140 5+ Cited Publications	Lactate Dehydrogenase	Cancer
(R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC₅₀s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.

HY-W040073S

Nifurtimox-d4	Isotope-Labeled Compounds Parasite Lactate Dehydrogenase	Cancer Infection
Nifurtimox-d₄ is deuterium labeled Nifurtimox. Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).

HY-129630S

Tetrahydrocortisol-d5	Endogenous Metabolite	Metabolic Disease
Tetrahydrocortisol-d₅ is the deuterium labeled Tetrahydrocortisol. Tetrahydrocortisol is cortisol metabolite. The urinary Tetrahydrocortisol/Tetrahydrocortisone ratio decreases with increasing 11β-hydroxysteroid dehydrogenase (11β-HSD) activity[1][2].

HY-108325

Brequinar 5+ Cited Publications DUP785; NSC 368390	Dihydroorotate Dehydrogenase SARS-CoV Virus Protease DNA/RNA Synthesis	Cancer Infection Inflammation/Immunology
Brequinar (DUP785) is a potent inhibitor of *dihydroorotate dehydrogenase* (DHODH) with an IC₅₀ of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2** activity.

HY-156193

PF-07208254

Endogenous Metabolite Cardiovascular Disease

PF-07208254 is a potent inhibitor of BDK. PF-07208254 improves cardiometabolic endpoints in mice.

HY-101930

BMS-816336	11β-HSD	Metabolic Disease
BMS-816336 is a novel, potent and orally bioavailable inhibitor against *human 11β-hydroxysteroid* dehydrogenase type 1 (11β-HSD1) enzyme with an IC₅₀** of 3.0 nM.

HY-19540

GSK864 3 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
GSK864 is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC₅₀ values of 8.8, 15.2 and 16.6 nM.

HY-W040118

Galloflavin 1 Publications Verification	Lactate Dehydrogenase	Cancer
Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated K_is for pyruvate are 5.46 µM (LDH-A) and 15.06 µM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production.

HY-B0083S

Leflunomide-d4	Dihydroorotate Dehydrogenase	Cancer
Leflunomide-d₄ (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent[1][2].

HY-15374

Frentizole	Amyloid-β	Inflammation/Immunology
Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC₅₀ value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus.

HY-W051723

(R)-3-Hydroxybutanoic acid 3 Publications Verification (R)-(-)-3-Hydroxybutanoic acid; (R)-3-Hydroxybutyric acid	Endogenous Metabolite	Others
(R)-3-Hydroxybutanoic acid is a metabolite, and converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid has applications as a nutrition source and as a precursor for vitamins, antibiotics and pheromones.

HY-W078844

PfDHODH-IN-2	Dihydroorotate Dehydrogenase Parasite	Infection
PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC₅₀ of 1.11 µM. PfDHODH-IN-2 acts as an antimalarial agent and can be used for the research of malaria.

HY-12492

VER-246608	PDHK	Cancer
VER-246608 is a potent and ATP-competitive inhibitor of *pyruvate dehydrogenase* kinase (PDK) with IC₅₀s of 35 nM, 40 nM, 84 nM, and 91 nM for PDK-1, PDK-3, PDK-2, and PDK-4**, respectively.

HY-151560

hDHODH-IN-11	Dihydroorotate Dehydrogenase	Cancer
hDHODH-IN-11 is a potent human *dihydroorotate dehydrogenase* (hDHODH) inhibitor with an IC₅₀** value of 7.2 nM. hDHODH-IN-11 has low cytotoxicity. hDHODH-IN-11 can be used in research of acute myeloid leukemia (AML).

HY-100184

DSM265	Dihydroorotate Dehydrogenase Parasite	Infection
DSM265 is a long-duration inhibitor of P. falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC₅₀ of 8.9 nM. DSM265 can also inhibit the growth of Pf3D7 parasites with an EC₅₀ of 4.3 nM.

HY-135549

Fluxapyroxad	Fungal Antibiotic	Infection
Fluxapyroxad is a synthetic broad-spectrum fungicide for the control of fungal diseases. It works by inhibiting succinate dehydrogenase in complex II of the mitochondrial respiratory chain, resulting in inhibition of spore germination, germ tubes and mycelia growth within the fungus target species.

HY-114009

AKR1C1-IN-1

Others Neurological Disease

AKR1C1-IN-1 is a potent and selective inhibitor of human 20α-hydroxysteroid dehydrogenase (AKR1C1), with a K_i value of 4 nM for AKR1C1.

HY-135678

DHODH-IN-14	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-14 (Compound 7l) is a hydroxyfurazan analog of A771726. DHODH-IN-14 is a *dihydroorotate dehydrogenase* (DHODH) inhibitor with an IC₅₀ of 0.49 μM for rat liver DHODH**. DHODH-IN-14 can be used for rheumatoid arthritis.

HY-135677

DHODH-IN-13	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-13 (Compound 7a) is a hydroxyfurazan analog of A771726. DHODH-IN-13 is a *dihydroorotate dehydrogenase* (DHODH) inhibitor with an IC₅₀ of 4.3 μM for rat liver DHODH**. DHODH-IN-13 can be used for rheumatoid arthritis.

HY-135679

DHODH-IN-15	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-15 (Compound 7b) is a hydroxyfurazan analog of A771726. DHODH-IN-15 is a *dihydroorotate dehydrogenase* (DHODH) inhibitor with an IC₅₀ of 11 μM for rat liver DHODH**. DHODH-IN-15 can be used for rheumatoid arthritis.

HY-135619

DHODH-IN-4	Parasite Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection Inflammation/Immunology
DHODH-IN-4 (compound 17) is a human and Plasmodium falciparum *dihydroorotate dehydrogenase* (DHODH) inhibitor, with IC₅₀** values of 4 μM and 0.18 μM for PfDHODH and HsDHODH, respectively. DHODH-IN-4 (compound 17) possess antimalarial activity.

HY-W012926S

Dihydrouracil-13C4,15N2 5,6-Dihydrouracil-¹³C₄,¹⁵N₂	Endogenous Metabolite	Metabolic Disease
Dihydrouracil-¹³C₄,¹⁵N₂ is the ¹³C and ¹⁵N labeled Dihydrouracil[1]. Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient[2][3].

HY-135618

DHODH-IN-3	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-3 (compound 3) is a potent inhibitor of Human Dihydroorotate Dehydrogenases (HsDHODH) with an IC₅₀ value of 261 nM. DHODH-IN-3 binds to the the ubiquinone binding cavities in DHODH with a K_i^app of 32 nM. DHODH-IN-3 has the potential for malaria treatment.

HY-134438

Hexanoyl coenzyme A trilithium	Endogenous Metabolite	Metabolic Disease
Hexanoyl coenzyme A trilithium is a hexanoyl-based medium-chain fatty acyl coenzyme A that is present in all organisms. Hexanoyl coenzyme A trilithium can be used as a precursor for cannabinoid biosynthesis and acts as a competitive inhibitor of medium-chain acyl coenzyme A dehydrogenase (MCAD).

HY-147216

AXKO-0046 1 Publications Verification	Lactate Dehydrogenase	Cancer
AXKO-0046, indole derivative, is an uncompetitive *Lactate dehydrogenase* B (LDHB) selective inhibitor.AXKO-0046 has LDHB inhibitory activity with an EC₅₀** value of 42 nM.AXKO-0046 can be used for the research of cancer metabolism.

HY-123962

G6PD activator AG1 1 Publications Verification	Others	Metabolic Disease
G6PD activator AG1 is a potent and selective *glucose-6-phosphate dehydrogenase* (G6PD) activator with an EC₅₀** of 3 µΜ. G6PD activator AG1 reduces hemolysis of human erythrocytes.

HY-B1729

Phenoxyethanol	Bacterial	Infection
Phenoxyethanol has a broad spectrum of antimicrobial activity against various gram-negative and gram-positive bacteria. Phenoxyethanol is an uncouple agent in oxidative phosphorylation from respiration and competitively inhibits malate dehydrogenase. Phenoxyethanol is used as a preservative in cosmetic, vaccine, and textile, et al.

HY-100688

ML390	Dihydroorotate Dehydrogenase	Cancer
ML390 is a potent *dihydroorotate dehydrogenase* (DHODH)** inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models.

HY-109619

D4-abiraterone Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite	Androgen Receptor Cytochrome P450	Cancer
D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor.

HY-126241

RV01	Aldehyde Dehydrogenase (ALDH)	Inflammation/Immunology
RV01 is an analogue of resveratrol, inhibits DNA damage, reduces *acetaldehyde dehydrogenase* 2 (ALDH2) mRNA expression induced by ethanol, and exhibits hydroxyl radical scavenging activity. RV01 decreases iNOS** expression, with anti-neuroinflammatory activity.

HY-N2177

3-Dehydrotrametenolic acid	Lactate Dehydrogenase Apoptosis	Cancer
3-Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a *lactate dehydrogenase* (LDH)** inhibitor. 3-Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-Dehydrotrametenolic acid induces apoptosis and has anticancer activity.

HY-W040307B

Saccharopine hydrochloride L-Saccharopine hydrochloride	Endogenous Metabolite	Metabolic Disease
Saccharopine (L-Saccharopine) hydrochloride, a lysine degradation intermediate, is a mitochondrial toxin. Lysine and α-ketoglutarate are converted into Saccharopine hydrochloride by the lysine-ketoglutarate reductase. Saccharopine hydrochloride is then oxidized to α-aminoapidate semialdehyde and glutamate by the saccharopine dehydrogenase. Saccharopine hydrochloride impairs development by disrupting mitochondrial homeostasis.

HY-155004

SDH-IN-3	Antibiotic Fungal	Infection
SDH-IN-3 is a *succinate dehydrogenase* (SDH) inhibitor with an IC₅₀** of 7.2 μg/mL. SDH-IN-3 exhibits excellent antifungal activities against Nigrospora oryzae with an EC₅₀ of 1.9 μg/mL. SDH-IN-3 can be used for anti-infection research.

HY-19325

SKI2852	11β-HSD	Metabolic Disease
SKI2852 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC₅₀s of 1.6 nM and 2.9 nM against mHSD1 and hHSD1, respectively.

HY-N7393

Isomalt Palatinitol	Lactate Dehydrogenase	Metabolic Disease
Isomalt (Palatinitol), a well-tolerated, non-toxic polyol and a protein-stabilizing excipient, stabilizes *lactate dehydrogenase* (LDH)** moderately during freeze-drying, and performs better during storage. Isomalt is traditionally used as a sweetening agent in the food industry and as a tabletting excipient for pharmaceutical purposes.

HY-W040307

Saccharopine L-Saccharopine	Endogenous Metabolite	Metabolic Disease
Saccharopine (L-Saccharopine), a lysine degradation intermediate, is a mitochondrial toxin. Lysine and α-ketoglutarate are converted into Saccharopine by the lysine-ketoglutarate reductase. Saccharopine is then oxidized to α-aminoapidate semialdehyde and glutamate by the saccharopine dehydrogenase. Saccharopine impairs development by disrupting mitochondrial homeostasis.

HY-W015851

(R)-3-Hydroxybutanoic acid sodium 3 Publications Verification (R)-(-)-3-Hydroxybutanoic acid sodium; (R)-3-Hydroxybutyric acid sodium	Endogenous Metabolite	Metabolic Disease
(R)-3-Hydroxybutanoic acid sodium ((R)-3-Hydroxybutyric acid) is a metabolite converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid sodium can function as a nutrition source, and as a precursor for vitamins, antibiotics and pheromones.

HY-114459

Mutant IDH1-IN-4	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-4 (compound 434) is an inhibitor of *mutant Isocitrate dehydrogenase* 1 (IDH 1), with IC₅₀** values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells.

HY-114570

Tiazofurin NSC 286193; Riboxamide	Nucleoside Antimetabolite/Analog Orthopoxvirus	Cancer Infection
Tiazofurin (NSC 286193) is a synthetic nucleoside analogue with antineoplastic activity. Tiazofurin is anabolized intracellularly to tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of *IMP dehydrogenase* (IMPDH). Tiazofurin also has anti-orthopoxvirus** and anti-variola activities.

HY-112277

NCT-505	Aldehyde Dehydrogenase (ALDH)	Cancer
NCT-505 is a potent and selective *aldehyde dehydrogenase* (ALDH1A1) inhibitor, with an IC₅₀ of 7 nM, and weakly inhibits hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 (IC₅₀**s, >57, 22.8, 20.1, >57 μM).

HY-139983

SDH-IN-1	Fungal	Infection
SDH-IN-1 (compound 4i) is a *succinate dehydrogenase* (SDH) inhibitor with an IC₅₀ of 4.53 μM. SDH-IN-1 has potent antifungal activities. SDH-IN-1 displays potent activity against S. sclerotiorum (EC₅₀** of 0.14 mg/L).

HY-126254

BI-4924 1 Publications Verification	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC₅₀=3 nM) with excellent microsomal, as well as hepatocytic stability. Intracellular trapping of BI-4924 disrupts serine biosynthesis with an IC₅₀ of 2200 nM at 72 h.

HY-103394

TC HSD 21	Others	Cancer
TC HSD 21 is a potent *17β-hydroxysteroid* dehydrogenase type 3 (17β-HSD3) inhibitor with an IC₅₀** of 14 nM. TC HSD 21 shows excellent selectivity over 17β-HSD isoenzymes and nuclear receptors.

HY-B0199

Mycophenolate Mofetil 5+ Cited Publications RS 61443; TM-MMF	Drug Metabolite Apoptosis Endogenous Metabolite Bacterial	Cancer
Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of *inosine monophosphate dehydrogenase* (IMPDH)**. Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation.

HY-135666

DHODH-IN-8	Parasite Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-8 (Compound 27) is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC₅₀s of 0.13 μM and 47.4 μM, and K_is of 0.016 μM and 5.6 μM, respectively. DHODH-IN-8 has antimalarial activity.

HY-149323

SDH-IN-4	Fungal	Infection
SDH-IN-4 (compound B6) is a selective inhibitor against *succinate dehydrogenase* (SDH) with an IC₅₀** value of 0.28 μg/mL. SDH-IN-4 has highly efficient and broad-spectrum antifungal activity, against R. solani with an EC₅₀ value of 0.23 μg/mL.

HY-W017522S3

Adipic acid-13C	Endogenous Metabolite	Metabolic Disease
Adipic acid-¹³C is the ¹³C labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-156735

HSD17B13-IN-2

17β-HSD Cancer

HSD17B13-IN-2 (compound 1) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-2 has cell experimental activity.

HY-132171A

DSM705 hydrochloride	Dihydroorotate Dehydrogenase Parasite	Infection
DSM705 hydrochloride, an orally active antimalarial compound, is a pyrrole-based *Dihydroorotate Dehydrogenase* (DHODH)** inhibitor. DSM705 hydrochloride exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites (IC₅₀=95, 52 nM for P. falciparum and P. vivax DHODH, respectively), with no inhibition of mammalian DHODHs.

HY-W017522S

Adipic acid-d10	Endogenous Metabolite	Metabolic Disease
Adipic acid-d₁₀ is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S2

Adipic acid-d4	Endogenous Metabolite	Metabolic Disease
Adipic acid-d₄ is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-D0018

DCIP sodium Dichlorophenylindophenol sodium; DCPIP sodium; Indochlorophenol sodium	Biochemical Assay Reagents	Others
DCIP sodium is a blue dye commonly used in various biochemical and biotechnological applications as an indicator of redox reactions. DCIP sodium has unique chemical properties that change color according to the oxidation state of the substance being tested. It is commonly used in enzyme assays, such as measuring the activity of succinate dehydrogenase, or in protein quantification methods, such as the Lowry assay.

HY-W017522S1

Adipic acid-13C6	Endogenous Metabolite	Metabolic Disease
Adipic acid-¹³C₆ is the ¹³C labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S4

Adipic acid-d8	Endogenous Metabolite	Metabolic Disease
Adipic acid-d₈ is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-156736

HSD17B13-IN-3	17β-HSD	Cancer
HSD17B13-IN-3 (compound 2) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-3 does not have cell experimental activity.

HY-W017522S5

Adipic acid-d4-1	Endogenous Metabolite	Metabolic Disease
Adipic acid-d₄-1 is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-139161

Penflufen	Fungal	Infection
Penflufen is a highly efficient, broad-spectrum succinate dehydrogenase inhibitor (SDHI). Penflufen can be used as a fungicide and has broad bioactivity against many fungal diseases, including potato black scurf, wheat sharp eyespot, rice sheath blight, and root rot in peanut and other similar fungal diseases.

HY-W011243

11alpha-Hydroxyprogesterone	Others	Cardiovascular Disease
11alpha-Hydroxyprogesterone is the inactive analogue of 11beta-Hydroxyprogesterone (HY-N2337), and can be used as an experimental control. 11beta-Hydroxyprogesterone is a potent inhibitors of 11β-Hydroxysteroid dehydrogenase; also activates human mineralocorticoid receptor in COS-7 cells with an ED₅₀ of 10 nM.

HY-13423

Tenovin-1 3 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-1, a p53 activator, protects p53 from MDM2-mediated degradation. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also a *dihydroorotate dehydrogenase* (DHODH)** inhibitor.

HY-130251

DS18561882 5+ Cited Publications	Methylenetetrahydrofolate Dehydrogenase (MTHFD)	Cancer
DS18561882 is a highly potent, isozyme-selective *methylenetetrahydrofolate dehydrogenase* 2 (MTHFD2) inhibitor with an IC₅₀ value of 0.0063 μM. DS18561882 also has inhibitory effect on MTHFD1 (IC₅₀**=0.57 μM). DS18561882 exhibits a good oral pharmacokinetic profile.

HY-N0157

Orotic acid 1 Publications Verification 6-Carboxyuracil; Vitamin B13	Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats.

HY-16214

FX-11 10+ Cited Publications LDHA Inhibitor FX11	Lactate Dehydrogenase Apoptosis Reactive Oxygen Species	Cancer
FX-11 is a potent, selective, reversible and competitive *lactate dehydrogenase* A (LDHA) inhibitor, with a K_i of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor** activity in lymphoma and pancreatic cancer xenografts.

HY-129239

Farudodstat 2 Publications Verification ASLAN003	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Apoptosis	Cancer
Farudodstat (ASLAN003) is an orally active and potent *Dihydroorotate Dehydrogenase* (DHODH) inhibitor with an IC₅₀ of 35 nM for human DHODH enzyme. Farudodstat inhibits protein synthesis via activation of AP-1 transcription factors. Farudodstat induces apoptosis** and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice.

HY-N0157A

Orotic acid zinc	Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Orotic acid (zinc), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid (zinc) is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid (zinc) can induce hepatic steatosis and hepatomegaly in rats.

HY-149814

PDK-IN-1	PDHK HSP	Cancer
PDK-IN-1 (compound 7o) is a *pyruvate dehydrogenase* kinase (PDK) inhibitor. PDK-IN-1 shows IC₅₀ values of 0.03 and 0.1 μM for PDK1 and HSP90**, respectively. PDK-IN-1 targets PDH/PDK axis thus reducing efficiently the tumor mass.

HY-149877

hDHODH-IN-12	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
hDHODH-IN-12 is a potent DHODH inhibitor with an IC₅₀ value of 0.421 μM. DHODH is the rate-limiting enzyme in the de novo synthesis of pyrimidine which is essential in DNA/RNA Synthesis. hDHODH-IN-12 is present in the inner membrane of human mitochondria.hDHODH-IN-12 can be used for the research of lung cancer.

HY-146552

PDHK-IN-4	PDHK	Cancer Metabolic Disease
PDHK-IN-4 (Compound 30) is a potent inhibitor of PDHK with IC₅₀s of 0.0051 and 0.0122 μM for PDHK2 and PDHK4, repectively. Pyruvate dehydrogenase kinases (PDHKs) are fascinating agent targets for numerous diseases, including diabetes and cancers. PDHK-IN-4 has the potential for the research of cancer diseases.

HY-10545

Taribavirin	HBV HCV	Infection
Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin, is a ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.

HY-18767

Ivosidenib 5+ Cited Publications AG-120	Isocitrate Dehydrogenase (IDH)	Cancer Metabolic Disease
Ivosidenib (AG-120) is an orally active inhibitor of *isocitrate dehydrogenase* 1 mutant (mIDH1) enzyme**, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity.

HY-145381

11β-HSD1-IN-6	11β-HSD	Metabolic Disease
11β-HSD1-IN-6 is a an *11β-HSD-1* inhibitor. The 11β hydroxysteroid dehydrogenase enzymes (11β-HSDs) mediate the interconversion of the glucocorticoid (GC) corticosterone or cortisol to an inactive form, 11-dehydrocorticosterone (11-DHC) or Cortisone, respectively.

HY-B1729S1

Phenoxyethanol-d4	Bacterial	Infection
Phenoxyethanol-d₄ is the deuterium labeled Phenoxyethanol[1]. Phenoxyethanol has a broad spectrum of antimicrobial activity against various gram-negative and gram-positive bacteria. Phenoxyethanol is an uncouple agent in oxidative phosphorylation from respiration and competitively inhibits malate dehydrogenase. Phenoxyethanol is used as a preservative in cosmetic, vaccine, and textile, et al[2].

HY-107124

BMS-770767	11β-HSD	Metabolic Disease
BMS-770767 is an 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor in type 2 diabetes. 11β-HSD1 is an important enzyme that is widely expressed in liver, adipose tissue and other tissues and plays an important role in metabolic diseases such as diabetes and obesity.

HY-148814

BI-3231	17β-HSD	Metabolic Disease
BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC₅₀s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases.

HY-10545A

Taribavirin hydrochloride	HBV HCV	Infection
Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.

HY-B1729S

Phenoxyethanol-d2	Antibiotic	Infection
Phenoxyethanol-d₂ is the deuterium labeled Phenoxyethanol[1]. Phenoxyethanol has a broad spectrum of antimicrobial activity against various gram-negative and gram-positive bacteria. Phenoxyethanol is an uncouple agent in oxidative phosphorylation from respiration and competitively inhibits malate dehydrogenase. Phenoxyethanol is used as a preservative in cosmetic, vaccine, and textile, et al[2].

HY-144669

ALDH1A3-IN-2	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH1A3-IN-2 (Compound 15) is a potent inhibitor of ALDH1A3 with an IC₅₀ of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH1A3-IN-2 has the potential for the research of cancer diseases.

HY-146554

PDHK-IN-5	PDHK	Cancer
PDHK-IN-5 (Compound 19) is a potent inhibitor of PDHK with IC₅₀s of 0.006 and 0.0329 μM for PDHK2 and PDHK4, repectively. Pyruvate dehydrogenase kinases (PDHKs) are fascinating agent targets for numerous diseases, including diabetes and cancers. PDHK-IN-5 has the potential for the research of cancer diseases.

HY-101930B

(R)-BMS-816336	11β-HSD	Metabolic Disease
(R)-BMS-816336 (Compound 6n-1) is a potent and orally active inhibitor of human, mouse and *cynomolgus monkey 11β-hydroxysteroid* dehydrogenase type 1 (11β-HSD1) enzyme with IC₅₀**s of 14.5 nM, 50.3 nM and 16 nM, respectively .

HY-144671

ALDH3A1-IN-2	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH3A1-IN-2 (Compound 19) is a potent inhibitor of ALDH3A1 with an IC₅₀ of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH3A1-IN-2 has the potential for the research of cancer diseases.

HY-10555

AMG-221	11β-HSD	Metabolic Disease
AMG-221 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with a K_i of 12.8 nM in vitro biochemical scintillation proximity assay (SPA) and an IC₅₀ of 10.1 nM in cell-based assays. AMG-221 can be used for the research of type 2 diabetes.

HY-143306

IDH1 Inhibitor 5	Isocitrate Dehydrogenase (IDH)	Cancer
IDH1 Inhibitor 5 (compound 2) is an IDH1 (isocitrate dehydrogenase 1) inhibitor. IDH1 Inhibitor 5 inhibits MOG cells and wild-type IDH1 glioma cells with expressing exogenous mutant IDH1 R132H protein with IC₅₀s of 64.4 and 34.9 nM, respectively.

HY-N0108

Physcion 5 Publications Verification Parietin; Rheochrysidin	Bacterial	Cancer Infection Inflammation/Immunology
Physcion (Parietin) is an anthraquinone isolated from traditional Chinese medicine Radix et Rhizoma Rhei, acts as an inhibitor of 6-phosphogluconate dehydrogenase, with an IC₅₀ and a K_d of 38.5 μM and 26.0 μM, respectively. Physcion (Parietin) exhibits laxative, hepatoprotective, anti-inflammatory, anti-microbial, anti-proliferative and anti-tumor effects.

HY-N0108S

Physcion-d3 Parietin-d₃; Rheochrysidin-d₃	Isotope-Labeled Compounds Bacterial	Cancer Infection Inflammation/Immunology
Physcion-d₃ (Parietin-d₃) is the deuterium labeled Physcion (HY-N0108). Physcion acts as an inhibitor of 6-phosphogluconate dehydrogenase, with an IC₅₀ and a K_d of 38.5 μM and 26.0 μM, respectively. Physcion exhibits laxative, hepatoprotective, anti-inflammatory, anti-microbial, anti-proliferative and anti-tumor effects.

HY-135954A

PDK4-IN-1 hydrochloride 1 Publications Verification	PDHK Apoptosis	Cancer Metabolic Disease Inflammation/Immunology
PDK4-IN-1 hydrochloride is an anthraquinone derivative and a potent and orally active *pyruvate dehydrogenase* kinase 4 (PDK4) inhibitor with an IC₅₀ value of 84 nM. PDK4-IN-1 hydrochloride potently represses cellular transformation and cellular proliferation and induces apoptosis**. PDK4-IN-1 hydrochloride has antidiabetic, anticancer and anti-allergic activity.

HY-10617

Rucaparib phosphate 25+ Cited Publications AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest *hexose-6-phosphate dehydrogenase* (H6PD)** inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research.

HY-149876

SDH-IN-5	Fungal	Infection
SDH-IN-5 (compound 7d) is a potent *succinate dehydrogenase* (SDH) inhibitor, with an IC₅₀ of 3.293 μM. SDH-IN-5 is also exhibits antifungal activity, with an EC₅₀** of 0.046 μg/mL against R. solani. SDH-IN-5 could significantly inhibit the growth of R. solani in rice leaves with excellent protective and curative efficacies.

HY-153129

EP2 receptor antagonist-2	Prostaglandin Receptor	Endocrinology
EP2 receptor antagonist-2 (CID891729) is an antagonist of EP2 receptor. EP2 receptor antagonist-2 inhibits the EP2 receptor activation induced by PGE2. EP2 receptor antagonist-2 also suppresses lactate dehydrogenase (LDH) release induced by N-methyl-D-aspartate (NMDA).

HY-B0199S

Mycophenolate Mofetil-d4	Isotope-Labeled Compounds Drug Metabolite Apoptosis Endogenous Metabolite	Cancer
Mycophenolate Mofetil-d₄ is the deuterium labeled Mycophenolate Mofetil. Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation[1].

HY-101813

Laflunimus HR325	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Prostaglandin Receptor	Inflammation/Immunology
Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of *dihydroorotate dehydrogenase* (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC₅₀ values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1** and -2 inhibitor.

HY-10617A

Rucaparib 25+ Cited Publications AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest *hexose-6-phosphate dehydrogenase* (H6PD)** inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research.

HY-W010342

6-Aminonicotinamide 4 Publications Verification	Others	Cancer
6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP⁺-dependent enzyme *glucose-6-phosphate dehydrogenase* (G6PD) inhibitor (K_i**=0.46 μM). 6-Aminonicotinamide interferes with glycolysis, resulting in ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin, in killing cancer cells.

HY-135954

PDK4-IN-1	PDHK Apoptosis	Cancer Metabolic Disease Inflammation/Immunology
PDK4-IN-1 is an anthraquinone derivative and a potent and orally active *pyruvate dehydrogenase* kinase 4 (PDK4) inhibitor with an IC₅₀ value of 84 nM. PDK4-IN-1 potently represses cellular transformation and cellular proliferation and induces apoptosis**. PDK4-IN-1 has antidiabetic, anticancer and anti-allergic activity.

HY-132174

CHIKV-IN-2	Flavivirus Dihydroorotate Dehydrogenase	Infection
CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV), with excellent cellular antiviral activity (EC₉₀=270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target *Dihydroorotate Dehydrogenase* (DHODH)**, which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools.

HY-124593

PTC299 1 Publications Verification	VEGFR Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of *dihydroorotate dehydrogenase* (DHODH)**. PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies.

HY-18056

PF-915275	Others	Metabolic Disease
PF-915275 is a potent, selective and orally active human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) inhibitor with a K_i of 2.3 nM and an EC₅₀ of 15 nM (in HEK293 cells). The dose-dependent effect of PF-915275 on conversion of cortisone to cortisol in primary human and monkey hepatocytes, with an EC₅₀ of 20 and 100 nM, respectively.

HY-12959

Repinotan BAY x 3702 free base	5-HT Receptor	Neurological Disease
Repinotan (BAY x 3702 free base) is a potent, selective, brain-penetrant and orally active 5-HT1A receptor agonist, with K_i values of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex), and 0.59 nM (rat hippocampus). Repinotan has a weak affinity for other related receptors. Repinotan has pronounced neuroprotective effects.

HY-Y0445A

Sodium dichloroacetate 10+ Cited Publications	PDHK Reactive Oxygen Species NKCC Apoptosis	Cancer
Sodium dichloroacetate is a metabolic regulator in cancer cells' mitochondria with anticancer activity. Sodium dichloroacetate inhibits PDHK, resulting in decreased lactic acid in the tumor microenvironment. Sodium dichloroacetate increases reactive oxygen species (ROS) generation and promotes cancer cell apoptosis. Sodium dichloroacetate also works as NKCC inhibitor.

HY-100012

CBR-5884 10+ Cited Publications	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
CBR-5884 is an active, selective inhibitor of *phosphoglycerate dehydrogenase* (PHGDH) with an IC₅₀ of 33 μM. CBR-5884 inhibits de novo serine synthesis** in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis.

HY-101930A

(Rac)-BMS-816336	11β-HSD	Metabolic Disease
(Rac)-BMS-816336 (Compound 6n) is a racemate of BMS-816336. (Rac)-BMS-816336 is a potent inhibitor of human and *mouse 11β-hydroxysteroid* dehydrogenase type 1 (11β-HSD1) enzyme with IC₅₀**s of 10 nM and 68 nM, respectively. (Rac)-BMS-816336 has good metabolic stability.

HY-122028

HSD-016	11β-HSD	Metabolic Disease
HSD-016 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC₅₀ values of 11, 1 and 8 nM against human, mouse and rat 11β-HSD1, respectively. HSD-016 can be used for type 2 diabetes research.

HY-18173

AZD8329	11β-HSD	Metabolic Disease
AZD8329 is a potent 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with an IC₅₀ of 9 nM for human 11β-HSD1, displays excellent selectivity versus 11β-HSD2, 17β-HSD1 and 17β-HSD3.

HY-B0817S

Pyridaben-d13	Parasite	Infection
Pyridaben-d₁₃ is the deuterium labeled Pyridaben[1]. Pyridaben is a mitochondrial electron transport inhibitor (METI) acaricide that promotes the formation of damaging oxygen and nitrogen radicals. Pyridaben selectively inhibits complex I (NADH dehydrogenase) with an IC50 value of 2.4 nM (assay sites: rat liver and bovine heart mitochondria). Pyridaben also significantly inhibits rat mitochondrial mtNOS function[2][3].

HY-15510B

Tenovin-6 Hydrochloride 4 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-6 Hydrochloride, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 Hydrochloride inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC₅₀s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 Hydrochloride also inhibits *dihydroorotate dehydrogenase* (DHODH)**.

HY-129101

(-)-Eseroline fumarate Eseroline fumarate	5-HT Receptor	Neurological Disease
(-)-Eseroline fumarate is a metabolic of Physostigmine (HY-N6608), an AChE inhibitor. (-)-Eseroline fumarate elicits a leakage of lactic acid dehydrogenase (LDH) from cancer cells. (-)-Eseroline fumarate also induces the release of adenine nucleotides and 5-hydroxytryptamine (5-HT) from neuronal cells, thus induce cell death. (-)-Eseroline fumarate inhibits the electrically evoked twitches of the mouse vas deferens and of the guinea-pig ileum.

HY-114226

Olutasidenib 1 Publications Verification FT-2102	Isocitrate Dehydrogenase (IDH)	Cancer Inflammation/Immunology
Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of *mutant Isocitrate dehydrogenase* 1 (IDH1), with IC₅₀** values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .

HY-114855

BT2 1 Publications Verification	Bcl-2 Family	Metabolic Disease
BT2 is a BCKDC kinase (BDK) inhibitor with an IC₅₀ of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a K_i value of 59 μM.

HY-102003A

Rucaparib camsylate AG014699 camsylate; PF-01367338 camsylate	PARP	Cancer
Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib camsylate is a modest *hexose-6-phosphate dehydrogenase* (H6PD)** inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research.

HY-155534

17β-HSD10-IN-1	Endogenous Metabolite	Others
17β-HSD10-IN-1 (compound 9) is an orally active inhibitor of *17β-hydroxysteroid* dehydrogenase type 10 (17β-HSD10)** with blood-brain permeability. 17β-HSD10-IN-1 doesn't result additional effects for mitochondrial off-targets and cytotoxic or neurotoxic effects.

HY-B0228S10

(R)-3-Hydroxybutanoic acid-13C2 sodium (R)-(-)-3-Hydroxybutanoic acid-¹³C₂ sodium; (R)-3-Hydroxybutyric acid-¹³C₂ sodium	Endogenous Metabolite	Metabolic Disease
(R)-3-Hydroxybutanoic acid-¹³C₂ (sodium) is the ¹³C labeled (R)-3-Hydroxybutanoic acid (sodium) (HY-W015851). (R)-3-Hydroxybutanoic acid (sodium) is a metabolite converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid sodium can function as a nutrition source, and as a precursor for vitamins, antibiotics and pheromones[1][2][3].

HY-15510

Tenovin-6 4 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC₅₀s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits *dihydroorotate dehydrogenase* (DHODH)**.

HY-102003

Rucaparib monocamsylate 2 Publications Verification AG014699 monocamsylate; PF-01367338 monocamsylate	PARP	Cancer
Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest *hexose-6-phosphate dehydrogenase* (H6PD)** inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research.

HY-B0968A

Trimetazidine 4 Publications Verification	Autophagy	Cardiovascular Disease
Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a *3-hydroxyacyl-CoA dehydrogenase* (HADHA)** inhibitor.

HY-155335

FPR2 agonist 3	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
FPR2 agonist 3 (compound CMC23) can limit the lactate dehydrogenase release in LPS (HY-D1056) -stimulated cultures and decrease the levels of pro-inflammatory IL-1β and IL-6. FPR2 agonist 3 decrease the level of phosphor-STAT3 via the STAT3/SOCS3 signaling pathway.

HY-W015851S

(R)-3-Hydroxybutanoic acid-13c sodium [2-13C]Sodium acetate; Sodium [2-13C]acetate; Sodium acetate-2-¹³C	Endogenous Metabolite	Metabolic Disease
(R)-3-Hydroxybutanoic acid-¹³C (sodium) is the ¹³C labeled (R)-3-Hydroxybutanoic acid sodium[1]. (R)-3-Hydroxybutanoic acid sodium ((R)-3-Hydroxybutyric acid) is a metabolite converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid sodium can function as a nutrition source, and as a precursor for vitamins, antibiotics and pheromones[2][3].

HY-B0968

Trimetazidine dihydrochloride 4 Publications Verification	Autophagy	Cardiovascular Disease
Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a *3-hydroxyacyl-CoA dehydrogenase* (HADHA)** inhibitor.

HY-157015

Antifungal agent 81	Fungal	Infection
Antifungal agent 81(G22)exhibitsexcellent in vitro antifungal activities against Valsa mali withIC₅₀values of 0.48 mg/L. Antifungal agent 81also exhibits excellent in vivo protective againstV. maliat 40 mg/L.

HY-13653

(-)-Epigallocatechin Gallate 25+ Cited Publications EGCG; Epigallocatechol Gallate	Endogenous Metabolite Apoptosis	Cancer Inflammation/Immunology
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma.

HY-B0157

Ketotifen HC 20-511	Endogenous Metabolite Histamine Receptor SARS-CoV Influenza Virus	Infection Endocrinology Inflammation/Immunology
Ketotifen (HC 20-511) is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention.

HY-B0240

Disulfiram Maximum Cited Publications 39 Publications Verification Tetraethylthiuram disulfide; TETD	Aldehyde Dehydrogenase (ALDH) Interleukin Related Pyroptosis Apoptosis	Metabolic Disease Cancer
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram + Cu²⁺ increases intracellular ROS levels triggering apoptosis of ovarian cancer stem cells^[1-6].

HY-146240

ALDH1A1-IN-3	Aldehyde Dehydrogenase (ALDH)	Metabolic Disease
ALDH1A1-IN-3 (compound 57) is an excellent and selective *aldehyde dehydrogenase* 1A1 (ALDH1A1) inhibitor with an IC₅₀** value of 0.379 μM. ALDH1A1-IN-3 can effectively improve glucose consumption in HepG2 cells. ALDH1A1-IN-3 can be used for researching glucose metabolism improvement.

HY-151199

Steroid sulfatase/17β-HSD1-IN-1	Others	Cancer Endocrinology
Steroid sulfatase/17β-HSD1-IN-1 is a potent steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor with an IC₅₀ value of 28 nM for cellular human steroid sulfatase. Steroid sulfatase/17β-HSD1-IN-1 can be used to research estrogen-dependent diseases.

HY-N12161

3-Acetyl-11-keto-ursolic acid	Others	Metabolic Disease
3-Acetyl-11-keto-ursolic acid (Compound 18) is a triterpenoid compound derived from Eriobotrya japonicaleaves. 3-Acetyl-11-keto-ursolic acid has 11B-hydroxysteroid dehydrogenase 1 (11b-HSD1) inhibitory activity. 3-Acetyl-11-keto-ursolic acid can be used for anti-diabetes research.

HY-B0157A

Ketotifen fumarate 1 Publications Verification HC 20511 fumarate	Histamine Receptor Endogenous Metabolite SARS-CoV Influenza Virus	Inflammation/Immunology Endocrinology Cancer
Ketotifen (HC 20-511) fumarate is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen fumarate can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen fumarate also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen fumarate can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention.

HY-150701

INCB13739	Glucocorticoid Receptor Mineralocorticoid Receptor 11β-HSD	Metabolic Disease
INCB13739 is an orally active, potent, selective and tissue-specific11β-HSD1 (11β-hydroxysteroid dehydrogenase 1) inhibitor, with IC₅₀ values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC), respectively. INCB13739 can be used for type 2 diabetes mellitus (T2DM) and obesity research.

HY-113466

4-Hydroxynonenal 4 Publications Verification 4-HNE	Aldehyde Dehydrogenase (ALDH) Endogenous Metabolite	Cancer Neurological Disease Cardiovascular Disease
4-Hydroxynonenal (4-HNE) is an α,β unsaturated hydroxyalkenal and an oxidative/nitrosative stress biomarker. 4-Hydroxynonenal is a substrate and an inhibitor of *acetaldehyde dehydrogenase* 2 (ALDH2)**. 4-Hydroxynonenal can modulate a number of signaling processes mainly through forming covalent adducts with nucleophilic functional groups in proteins, nucleic acids, and membrane lipids. 4-Hydroxynonenal plays an important role in cancer through mitochondria.

HY-B0968S

Trimetazidine-d8 dihydrochloride	Autophagy	Cardiovascular Disease
Trimetazidine-d₈ (dihydrochloride) is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].

HY-N0157S1

Orotic acid-13C,15N2 monohydrate 6-Carboxyuracil-¹³C,¹⁵N₂ monohydrate; Vitamin B13-¹³C,¹⁵N₂ monohydrate	Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Orotic acid-¹³C,¹⁵N₂ (monohydrate) is the ¹³C and ¹⁵N labeled Orotic acid[1]. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats[2][3][4].

HY-145286

IMPDH2-IN-2	Bacterial	Cancer Infection
IMPDH2-IN-2 is a potent inhibitor of inosine 5’-monophosphate dehydrogenase (IMPDH) with a K_i,app value of 14 μM, respectively. IMPDH2-IN-2 displays moderate antibacterial activity (MIC = 6.3 and 11 μM in minimal GAST/Fe and rich 7H9/ADC/Tween media, respectively). IMPDH2-IN-2 is a potential anti-tuberculosis agent.

HY-130502

Cholesterol 5beta,6beta-epoxide Cholesterol beta-epoxide	Biochemical Assay Reagents	Others
Cholesterol 5beta,6beta-epoxide is an oxidative metabolite of cholesterol formed by free-radical and non-radical oxidation of cholesterol at the 5,6 double bond. Induces lactate dehydrogenase (LDH) release and apoptosis in macrophage-differentiated U937 cells. Cholesterol 5beta,6beta-epoxide has been found in human fatty streaks and advanced atherosclerotic lesions, but not in normal aortic tissue.

HY-111262

ABT-384	11β-HSD	Metabolic Disease Neurological Disease
ABT-384 is a potent, selective 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. ABT-384 exhibits high affinity (K_i 0.1-2.7 nM) against rodent, monkey, and human 11β-HSD1. ABT-384 blocks regeneration of active cortisol. ABT-384 can be used for the research of Alzheimer’s disease (AD).

HY-113377

L-Glyceric acid	Endogenous Metabolite	Metabolic Disease
L-Glyceric acid is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid excretion to distinguish PH1 from PH2.

HY-151200

Steroid sulfatase-IN-4	Others	Endocrinology
Steroid sulfatase-IN-4 (Compound 16) is an irreversible steroid sulfatase (STS) inhibitor with an IC₅₀ of 25 nM against human STS. Steroid sulfatase-IN-4 can be used for the research of endometriosis.

HY-P3148

Astin B	Apoptosis Autophagy Reactive Oxygen Species JNK Bcl-2 Family Caspase	Metabolic Disease
Astin B is a orally active and potent cyclic pentapeptide, that can be isolated from Aster tataricus. Astin B has hepatotoxic effects in vitro and in vivo and that hepatic injury was primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B induces autophagy in L-02 cells, increases LC3-II and decreases p62 expression.

HY-113377A

L-Glyceric acid sodium	Endogenous Metabolite	Metabolic Disease
L-Glyceric acid sodium is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid sodium can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid sodium excretion to distinguish PH1 from PH2.

HY-13560

AVN-944 4 Publications Verification VX-944	Arenavirus DNA/RNA Synthesis Apoptosis Caspase Bcl-2 Family	Cancer Infection
AVN-944 (VX-944) is an orally active, potent, selective, noncompetitive and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). AVN-944 is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. AVN-944 is also an inhibitor of arenavirus RNA synthesis, and blocks arenavirus infection. AVN-944 has broad anti-cancer activities, and can be used for multiple myeloma (MM) and acute myeloid leukemia (AML) research.

HY-13653S

(+/-)-Epigallocatechin Gallate-13C3	Autophagy Reactive Oxygen Species HIV Ferroptosis Mitochondrial Metabolism Endogenous Metabolite	Cancer
(+/-)-Epigallocatechin Gallate-¹³C₃ is the ¹³C-labeled (-)-Epigallocatechin Gallate. (-)-Epigallocatechin Gallate is a tea flavonoid with potent antioxidant, antiinflammatory, and anticarcinogenic properties. (-)-Epigallocatechin Gallate is reported to inhibit EGFR signaling and thereby exert anticancer effects[1]. (-)-Epigallocatechin Gallate (EGCG) is a glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) inhibitor. Epigallocatechin-3-gallate induces oxidative phosphorylation (OXPHOS) by activating cytochrome c oxidase.

HY-146172

Antioxidant agent-3	Reactive Oxygen Species	Cancer Inflammation/Immunology
Antioxidant agent-3 (Compound 14q), an potent antioxidant, displays potent DPPH radicals scavenging activity and ABTS⁺ scavenging activity with IC₅₀s of 26.58 and 30.31 μM, respectively. Antioxidant agent-3 (Compound 14q) increases reactive oxygen species (ROS), superoxide dismutase (SOD) and glutathione (GSH), and reduced lactate dehydrogenase (LDH) in H₂O₂-treated HepG2 cells.

HY-150526

EGCG-4″-sulfate	Endogenous Metabolite Apoptosis	Cancer Inflammation/Immunology
EGCG-4″-sulfate is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate sulfate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. EGCG-4″-sulfate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma.

HY-114464S

11-Beta-hydroxyandrostenedione-d4 4-Androsten-11β-ol-3,17-dione-d₄	Isotope-Labeled Compounds Endogenous Metabolite 11β-HSD	Endocrinology
11-Beta-hydroxyandrostenedione-d₄ is the deuterium labeled 11-Beta-hydroxyandrostenedione. 11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). 11-Beta-hydroxyandrostenedione is a 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes inhibitor[1][2].

HY-155535

17β-HSD10-IN-2	Endogenous Metabolite	Neurological Disease
17β-HSD10-IN-2 (compound 11) is a benzothiazolylurea-based inhibitor，targeting to 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10)，a multifunctional mitochondrial enzyme. 17β-HSD10-IN-2 don't lead to mitochondrial off-targets and cytotoxic or neurotoxic effects. 17β-HSD10 inhibitors can be used for research in Alzheimer's disease (AD) and hormone-dependent cancer.

HY-114464

11-Beta-hydroxyandrostenedione 4-Androsten-11β-ol-3,17-dione	Endogenous Metabolite 11β-HSD	Endocrinology
11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). 11-Beta-hydroxyandrostenedione is a *11β-hydroxysteroid* dehydrogenase (11βHSD) isozymes** inhibitor. As 4-androstenedione increases, measuring plasma 11-Beta-hydroxyandrostenedione can distinguish the adrenal or ovarian origin of hyperandrogenism.

HY-131312

LY3410738 Mutant IDH1-IN-6	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-6 is a potent, selective and orally active *mutant isocitrate dehydrogenase* (IDH) inhibitor with IC₅₀s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes**, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes.

HY-13653R

(-)-Epigallocatechin Gallate (Standard) EGCG(Standard); Epigallocatechol Gallate (Standard)	Endogenous Metabolite Apoptosis	Cancer Inflammation/Immunology
(-)-Epigallocatechin Gallate (Standard) is the analytical standard of (-)-Epigallocatechin Gallate. This product is intended for research and analytical applications. (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma.

HY-151201

Steroid sulfatase/17β-HSD1-IN-3	Others	Cancer
Steroid sulfatase/17β-HSD1-IN-3 (compound 19) is a dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). Steroid sulfatase/17β-HSD1-IN-3 irreversibly inhibits hSTS activity with anIC₅₀ value of 27 nM. Steroid sulfatase/17β-HSD1-IN-3 can be used in the study of endometriosis and other estrogen-dependent diseases.

HY-113466S

4-Hydroxynonenal-d3 4-HNE-d₃	Isotope-Labeled Compounds Aldehyde Dehydrogenase (ALDH) Endogenous Metabolite	Cancer Neurological Disease Cardiovascular Disease
4-Hydroxynonenal-d₃ is the deuterium labeled 4-Hydroxynonenal. 4-Hydroxynonenal (4-HNE) is an α,β unsaturated hydroxyalkenal and an oxidative/nitrosative stress biomarker. 4-Hydroxynonenal is a substrate and an inhibitor of acetaldehyde dehydrogenase 2 (ALDH2). 4-Hydroxynonenal can modulate a number of signaling processes mainly through forming covalent adducts with nucleophilic functional groups in proteins, nucleic acids, and membrane lipids. 4-Hydroxynonenal plays an important role in cancer through mitochondria[1][2][3].

HY-152670

JC2-11	NOD-like Receptor (NLR) AIM2	Inflammation/Immunology
JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1.

HY-151202

Steroid sulfatase/17β-HSD1-IN-4	Others	Cancer
Steroid sulfatase/17β-HSD1-IN-4 (compound 37) is a dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). Steroid sulfatase/17β-HSD1-IN-4 irreversibly inhibits hSTS activity with anIC₅₀ value of 63 nM. Steroid sulfatase/17β-HSD1-IN-4 can be used in the study of endometriosis and other estrogen-dependent diseases.

HY-112289

IDH889	Isocitrate Dehydrogenase (IDH)	Cancer
IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of *isocitrate dehydrogenase* 1 (IDH1)*. IDH889 has potent selectivity for IDH1 R132 mutations, with IC₅₀s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1^R132H, IDH1^R132C and IDH1^wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC₅₀ of 0.014 μM.

HY-121744

PS10 1 Publications Verification	PDHK	Inflammation/Immunology
PS10 is a novel, potent and ATP-competitive pan-PDK inhibitor, inhibits all PDK isoforms with IC₅₀ of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (K_d= 239 nM) than for Hsp90 (K_d= 47 μM). PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy.PDK: pyruvate dehydrogenase kinase

HY-143234

mIDH1-IN-1	Isocitrate Dehydrogenase (IDH)	Cancer
mIDH1-IN-1 (compound 43) is a potent and selective mIDH1 (mutant isocitrate dehydrogenases 1) inhibitor, with an IC₅₀ of 961.5 nM. mIDH1-IN-1 potently inhibits intracellular 2-HG (2-hydroxyglutarate) production in HT1080 cells, with an EC₅₀ of 208.6 ± 8.0 nM. mIDH1-IN-1 shows a significant anti-proliferation activity on IDH1 mutant-U-87 cells, with an IC₅₀ of 41.8 nM. mIDH1-IN-1 is an antitumor agent, and can be used for IDH1 mutated solid tumors research.

HY-104042

Vorasidenib 3 Publications Verification AG-881	Isocitrate Dehydrogenase (IDH)	Cancer
Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual *mutant isocitrate dehydrogenases* 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC₅₀** ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K.

HY-155010

Steroid sulfatase/17β-HSD1-IN-5	Others	Metabolic Disease
Steroid sulfatase/17β-HSD1-IN-5 is a irreversible inhibitor of steroid sulfatase (STS) .Steroid sulfatase/17β-HSD1-IN-5 is a reversible and selective inhibitor of 7β-hydroxysteroid dehydrogenase type1 (17β-HSD1), with IC₅₀s of 43 nM and 6.2μM for 17β-HSD1 and 17β-HSD2, respectively. Steroid sulfatase/17β-HSD1-IN-5 can be used for metabolic disease (especially for endometriosis) research.

HY-155156

PF-07238025	Endogenous Metabolite	Cardiovascular Disease
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice.

HY-112289B

(1R)-IDH889	Isocitrate Dehydrogenase (IDH)	Cancer
(1R)-IDH889 is the inactive isomer of IDH889 (HY-112289), and can be used as an experimental control. IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of *isocitrate dehydrogenase* 1 (IDH1)*. IDH889 has potent selectivity for IDH1 R132 mutations, with IC₅₀s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1^R132H, IDH1^R132C and IDH1^wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC₅₀ of 0.014 μM.

HY-155157

PF-07247685	Endogenous Metabolite	Cardiovascular Disease
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice.

HY-B1588S

Carbenoxolone-d4	Amyloid-β HIV 11β-HSD	Infection Inflammation/Immunology Neurological Disease
Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

Cat. No.	Product Name

Cat. No.	Product Name	Type

Cat. No.	Product Name	Type

Cat. No.	Product Name	Target	Research Area

Cat. No.	Product Name	Target	Category

Species:	Human (60) Mouse (11) Rat (3) E.coli (1)
Tag:	His (84) SUMO (6) Tag Free (31) Strep (14) Myc (1) GST (9) CL7 (1)
Source:	HEK293 (14) E. coli Cell-free (3) Sf9 insect cells (13) P. pastoris (3) E. coli (90)

Cat. No.	Product Name	Species	Source

Cat. No.	Product Name

Cat. No.	Product Name	Application	Reactivity

Cat. No.	Product Name		Classification

11������-Hydroxysteroid Dehydrogenase Inhibitors

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

11��-Hydroxysteroid Dehydrogenase Inhibitors

Natural
Products